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ABSTRACT
Host-pathogen interactions of secreted and surface Staphylococcus aureus factors
Publication No. ____________
Vanessa Vazquez
Supervisory Professor: Magnus Höök, Ph.D.

Staphylococcus aureus is an opportunistic bacterial pathogen that can infect
humans and other species. It utilizes an arsenal of virulence factors to cause disease,
including secreted and cell wall anchored factors. Secreted toxins attack host cells, and
pore-forming toxins destroy target cells by causing cell lysis. S. aureus uses cell-surface
adhesins to attach to host molecules thereby facilitating host colonization. The Microbial
Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) are a family
of cell-wall anchored proteins that target molecules like fibronectin and fibrinogen. The
Serine-aspartate repeat (Sdr) proteins are a subset of staphylococcal MSCRAMMs that
share similar domain organization. Interestingly, the amino-terminus, is composed of three
immunoglobulin-folded subdomains (N1, N2, and N3) that contain ligand-binding activity.
Clumping factors A and B (ClfA and ClfB) and SdrG are Sdr proteins that bind to fibrinogen
(Fg), a large, plasma glycoprotein that is activated during the clotting cascade to form fibrin.
In addition to recognizing fibrinogen, ClfA and ClfB can bind to other host ligands.
Analysis of S. aureus strains that cause osteomyelitis led to the discovery of the
bone-sialoprotein-binding protein (Bbp), an Sdr protein.

Because several MSCRAMMs

target more than one molecule, I hypothesized that Bbp may recognize other host proteins.
A ligand screen revealed that the recombinant construct BbpN2N3 specifically recognizes
human Fg. Surface plasmon resonance was used to determine the affinity of BbpN2N3 for
Fg, and a dissociation constant of 540 nM was determined. Binding experiments performed
with recombinant Fg chains were used to map the binding of Bbp N2N3 to the Fg Aα chain.
iv

Additionally, Bbp expressed on the surface of Lactococcus lactis and S. aureus Newman
bald mediated attachment of these bacteria to Fg Aα.

To further characterize the

interaction between the two proteins, isothermal titration calorimetry and inhibition assays
were conducted with synthetic Fg Aα peptides. To determine the physiological implications
of Bbp binding to Fg, the effect of Bbp on fibrinogen clotting was studied. Results show that
Bbp binding to Fg inhibits the formation of fibrin. The consequences of this interaction are
currently under investigation.
Together, these data demonstrate that human Fg is a novel ligand for Bbp. This
study indicates that the MSCRAMM Bbp may aid in staphylococcal attachment by targeting
both an extracellular matrix and a blood plasma protein. The implications of these novel
findings are discussed.
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CHAPTER I
Introduction

Staphylococcus aureus is an opportunistic pathogen that causes a multitude of
diseases in humans and other species. It was discovered in the 1880s by Sir Alexander
Ogston as a cause of abscess infections, and its name originates from the Greek “staphyle”
and “kokkos” for “bunch of grapes” and the Latin “aureus” for “golden” because the
organism exists in clusters, and its colonies are yellow in color (1).

S. aureus is a gram-

positive organism that contains a cell wall composed of peptidoglycan and lipoteichoic acid.
The bacterium is catalase-positive, ferments mannitol, produces coagulase, and is not
motile. Although S. aureus is aerobic and grows best at 30-37°C, it tolerates growth at low
oxygen, under high osmotic pressure and at a wide temperature range (82) (12).

Types of S. aureus infections
Approximately 30-50% of healthy humans are colonized on the skin or nares with S.
aureus, and 20% of the population is considered to be persistent carriers.
carriage of the bacterium increases the risk of developing infections.

Persistent
Additionally,

individuals with acquired immune deficiency syndrome, diabetes, or post-surgery are at
increased risk of developing infections. Nosocomial infections are obtained by patients who
are currently undergoing treatment for another complication, especially by post-operative
patients (82).
S. aureus has the ability to cause different diseases. Infections range from mild skin
diseases like boils and pimples to more invasive illnesses. Uncomplicated skin and soft
tissue infections (SSTIs) include cellulitis, impetigo, and furuncles (82). Fortunately, these
infections can be successfully treated by surgical drainage and antibiotics (92).
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Contrastingly, patients with complicated SSTIs may present with tissue necrosis and
sepsis. They require admission into the hospital because they are at high risk of mortality
or limb-loss (92).

Prolonged uncomplicated SSTIs can also lead to development of

osteomyelitis or necrotizing fasciitis (31).

Furthermore, individuals may suffer from

recurrent SSTIs, which may be remedied by decolonization (31).
Bacteremia is the presence of bacteria in the blood. The source of the systemic
bacteria may be a localized focus of infection (72). Consequences of bacteremia arise as
the bacteria leave the bloodstream and colonize other tissues like the kidney or
endocardium.

Bacteremia may also lead to life-threatening sepsis.

S. aureus sepsis

involves systemic inflammation, and severe sepsis includes acute organ failure. Sepsis is
usually associated with bacteremia, and can be secondary to bacterial infection of the
urinary tract, bone, kidney, or lungs (49) (53). Patients can be admitted into the intensive
care unit for treatment, which can last for a few weeks.
S. aureus is the leading cause of osteomyelitis, characterized as an acute or a
chronic bone infection. Pediatric patients often suffer from the hematogeneous form of
osteomyelitis, which is accompanied by a fever.

Hematogeneous osteomyelitis usually

develops in long bones, like the femur and tibia, after colonization from the blood (115)
(117). In adults, osteomyelitis is usually developed due to spread of a soft tissue infection
or by introduction of S. aureus bacteria after trauma to the bone (115).
The second leading cause of food-borne illness is S. aureus.

Gastroenteritis is

characterized by nausea, abdominal cramps, diarrhea, and vomiting (7). Disease develops
approximately 30 minutes to 8 hours after ingestion of contaminated food (7) (73).

In

addition to its fast onset, non-life-threatening S. aureus gastroenteritis can subside within
24 hours of illness (73).

Although rare, gastroenteritis can lead to death, and elderly

individuals have a higher incidence of mortality (7).
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S. aureus is a causative agent of toxic shock syndrome (TSS), a severe disease
characterized by high fever, capillary leakage, hypotension, and often involves rash,
diarrhea and vomiting, and disseminated intravascular coagulation. S. aureus is considered
the sole etiology of TSS associated with tampon use in women, where there is also a
presence of ulcerative vaginitis (27). TSS is a major problem in pediatric burns, and it is the
most frequent cause of unexpected deaths in these patients (141). Currently, pediatric burn
cases have surpassed the amount of menstruation-related TSS (141).
S. aureus infections can cause pneumonia, an infection of the lungs. Necrotizing
pneumonia, which is characterized by inflammation, vascular leakage, and tissue
destruction in the lungs is severe (23). S. aureus is the most frequently isolated pathogen
from patients suffering from ventilator-associated pneumonia due to colonization of the
lower airways after mechanical ventilation (4).
Infective endocarditis is a complication of S. aureus disease with a mortality rate of
20-30%.

Symptoms of disease are fever and fatigue.

It involves infection of the

endovasculature and, commonly, implanted materials like prosthetic heart valves (136).
Pediatric endocarditis is associated with children suffering from congenital heart disease
(2). A recent report found that S. aureus was the etiologic agent of infective endocarditis in
40% of the study group (2).

S. aureus antibiotic resistance and therapy
S. aureus has acquired the ability to resist the action of antibiotics (29). Methicillinresistant S. aureus (MRSA) has become predominant in hospital settings, accounting for
the majority of nosocomial infections worldwide (82).
hospital associated-MRSA (HA-MRSA).

These strains are referred to as

Patients with HA-MRSA have established risk

factors such as prolonged hospitalization, prolonged antimicrobial therapy, surgical
procedures, dialysis, indwelling vascular devices, and proximity to patients in the hospital
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who are infected or colonized with MRSA (82). However, MRSA cases have been recently
reported in healthy individuals with no established risk factors. Because these infections
are apparently acquired in the community and are not related to the hospital environment,
they are referred to as community-associated MRSA (CA-MRSA) (59) (51). CA-MRSA
cases are now being reported all over the world, and their numbers are climbing. Infections
due to CA-MRSA seem to primarily affect children and young adults with no predisposing
factors. Contrary to HA-MRSA, CA-MRSA strains are susceptible to most antimicrobials
except for β-lactams (32), but due to the rapid onset of complications, treatment is often
ineffective.
Antibiotic resistance may arise by three mechanisms.

The first is acquired

resistance via a horizontal transfer, from other bacteria, of genes that encode for a
resistance-conferring molecule, commonly, the mecA gene product, which is a penicillinbinding protein. Secondly, chromosomal mutations can give rise to resistance. The third
mechanism is antibiotic selection (18).
Antibiotics may select for resistant organisms by killing the susceptible population
and leaving only the resistant bacteria, which then multiply causing an antibiotic-resistant
infection (122).

Studies suggest that some antibiotics may be better at selecting for

resistance than others due to the ability of a particular compound to possess higher
diffusion capabilities, as is the case of fluoroquinolones (122). Additionally secretion of the
antibiotic into the individual’s sweat could eradicate susceptible bacteria on the skin, which
has been shown for ciprofloxacin (61). It has been postulated that vancomycin resistance
may be associated with selection on strains colonizing the intestines.

It is generally

believed that vancomycin resistance frequency decreases as use of vancomycin decreases
(122).
The standard therapies for S. aureus infections are antibiotics.

Nafcillin and

oxacillin are the common therapeutics for susceptible S. aureus strains. Due to increased
5

development of resistance, rifampin, is not used alone but in combination with other
antibiotics, like nafcillin or vancomycin (37).

SSTIs and CA-MRSA are treated with

clindamycin, trimethoprim-sulfamethoxazole, or doxycycline (52).

Vancomycin is the

preferred treatment for other MRSA infections and for endocarditis (93).

However,

pneumonia and bone infections are treated with linezolid and clindamycin, respectively, due
to their abilities to penetrate tissues (52). New studies suggest the use of daptomycin
instead of standard therapy for endocarditis (64), possibly due to its lowered toxicity (41).

S. aureus pathogenesis
S aureus causes disease by attaching to host tissues, which it will subsequently
colonize.

Following these events, S. aureus establishes infection by killing host cells,

interfering with host pathways, evading the immune response, and spreading to other sites
(82). Furthermore, bacteria can form biofilms, which are difficult to treat with antibiotics. In
order to accomplish infection, S. aureus has an arsenal of virulence factors.

Adhesins
Adhesins are surface proteins used by the bacteria to attach to host molecules (39).
After protein expression, they are secreted. Following transport, adhesins are anchored to
the cell wall peptidoglycan by a sortase enzyme via a motif at the carboxy terminus (94).
The LPXTG motif is used by sortase A to covalently link adhesins to the peptidoglycan via a
transpeptidase reaction (94).

Specifically, the sortase cleaves the bond between the

threonine and the glycine, and the protein is anchored to the wall at the pentaglycine
crossbridges. Sortase B uses the NPQTN motif (85). Using sequence analysis to identify
staphylococcal proteins containing the LPXTG or NPQTN motif, 22 cell-wall anchored
proteins have been identified, and a function has been attributed to half of these putative
adhesins.
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Microbial

surface

components

recognizing

adhesive

matrix

molecules

(MSCRAMMs) are cell-wall anchored proteins that adhere to the host extracellular matrix or
serum proteins (99).

All of the characterized adhesins are MSCRAMMs.

They target

collagen, fibronectin, elastin, fibrinogen, and other molecules. They are redundant in their
specificity, as S. aureus expresses at least two MSCRAMMs that recognize fibronectin, two
that bind to heme, and at least four proteins that target fibrinogen. While the reason for this
redundancy is unknown, our laboratory and others are working to elucidate the reason for
this phenomenon and speculate the following reasons. First, some of the host proteins, like
fibrinogen and fibronectin, are larger than 300,000 daltons and are composed of different
polypeptide chains or different motifs that are involved in many reactions with other host
cells, plasma proteins, or extracellular matrix.

Secondly, the MSCRAMMs for which a

ligand-binding site has been characterized appear to target many different sites within the
same protein. This is the case for fibrinogen-binding MSCRAMMs (43) (22) (131).
MSCRAMMs share secondary structure similarities, although their linear sequence
may contain little identity. The domain organization of many MSCRAMMs can be described
from amino to carboxy terminus (Figure 1-1). Approximately the first 30 residues encode a
signal sequence that targets the protein for transport to the cell surface (94). Next, the A
domain has been characterized as the ligand-binding domain. C-terminal to the A domain,
MSCRAMMs possess one or two repeat regions. Some of these repeated domains are
believed to act as stalks that help the adhesin extend away from the cell surface. At the
carboxy terminus, there is a wall-spanning region, followed by a membrane-spanning
region. Between the latter two domains is the LPXTG anchoring motif (39).

Protein A
Protein A may be the most characterized surface protein of S. aureus. Protein A
binds to the plasma protein, von Willebrand factor (vWF) (57). This interaction can mediate
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Figure 1-1. Domain organization of MSCRAMMs. Fibronectin binding protein A (FnbpA)
(A), Collagen adhesin (Cna) (B), Clumping factor A (ClfA) (C), Protein A (Spa) (D). S:
signal sequence; A: amino terminal A domain; B: B repeats; R: Serine-Aspartate repeats;
W: wall spanning region; M: membrane spanning region; Wr: octapeptide repeat; Wc: nonrepeated domain. Reprinted from Trends in Microbiology, 6 (12), TJ Foster and M Hook,
Surface protein adhesins of Staphylococcus aureus, 484-488, 1998, with permission from
Elsevier Limited (39).
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attachment of S. aureus bacteria to vWF coated materials under shear flow forces (57).
Protein A has also been characterized as a tumor necrosis factor receptor protein 1
(TNFR1)-binding protein (48). This interaction triggers airway inflammation in a murine
pneumonia model (47). The most studied function of Protein A is its binding to the Fc
region of immunoglobulin heavy chain (38).

The structure of the binding domain in

complex with the Fc fragment has been solved (24). In humans, Protein A can bind to IgM,
IgA, and IgE but not as readily as it binds to IgG. Typically, antibodies recognize bacterial
determinants with the variable region and bind to their cell-surface receptors via the Fc
region. Because antibodies bind to Protein A via their Fc region, they are not available to
ligate Fc receptors to stimulate immune clearance. Via its interaction with IgG, Protein A
mediates an inhibition of phagocytosis. Furthermore, Protein A mutants are phagocytosed
more readily that wild-type (50).

Fnbps
S. aureus encodes two fibronectin binding proteins, FnbpA and FnbpB that also
share similar domain organization (see Figure 1-1).

They have been shown to confer

binding of bacteria to fibronectin type I modules. S. aureus has long been considered to be
an extracellular pathogen; however, FnbpA and FnbpB can mediate cell invasion by a
mechanism that involves forming a fibronectin bridge with host cell α5β1 integrins (40).
Additionally, the Fnbps are capable of binding to fibrinogen, and FnbpA also binds to
elastin. Interestingly, FnbpA binds to fibrinogen and elastin via the same site (66).

Cna
Collagen is targeted by the collagen binding adhesin, Cna. This protein has been
shown to increase the virulence of S. aureus in a murine septic arthritis model, and it may
also play a role in endocarditis (26) (60). Moreover, Cna was shown to be important for
9

hematogeneous spread in a murine osteomyelitis study (28). The structures of both the
apo-form and Cna in complex with a synthetic collagen peptide have been solved, and the
collagen-hug model has been proposed based on experimental data (142).
Cna binds to collagen via the N1 and N2 domains, which are connected by a linker
region. The pocket between the N1 and N2 domains accommodates the binding of the
triplex helix. Upon ligand binding, Cna and Ace wrap around or “hug” the collagen peptide,
resulting in a tunnel formed by the linker and the N1 and N2 domains where the peptide
can be held (Figure 1-2) (142).

Isds
Iron-responsive surface determinants (Isd) proteins are another family of cell-wall
anchored proteins. In order to survive in host systems, S. aureus must acquire iron, which
is usually in complex with other molecules in the form of porphyrins or transferrin. IsdA and
IsdC (86) can bind to heme; whereas IsdB recognizes heme and hemoglobin (83). A recent
report determined the ability of IsdB to bind to the platelet integrin αIIbβ3 which leads to
platelet adhesion and aggregation (21). IsdH can bind to haptoglobin in order to sequester
the iron. Interestingly, the Isd proteins are found in an operon that also encodes for the
sortase B and transporter proteins IsdDEF (86).

Clfs
The clumping factors A and B (ClfA, ClfB) also target many ligands. Their basic
domain organization is very similar: an amino-terminal ligand-binding domain and a carboxy
terminal serine-aspartate repeat (SD) region.

Thus, ClfA and ClfB are part of the Sdr

subfamily of MSCRAMMs (Figure 1-3). The ligand-binding subdomain constructs of both
proteins have been crystallized and the structure of ClfA in complex with a fibrinogen

10

Figure 1-2. Cartoon representation of the collagen hug model. (A) Collagen interacts with
the N2 domain. (B) The linker between N1 and N2 wraps the N1 around collagen (C)
Collagen is latched into position and N1 and N2 residues interact. Reprinted by
permission from MacMillan Publishers Ltd: EMBO Journal, Y Zong, Y Xu, X Liang, DR
Keene, A Höök, S Gurusiddappa, M Höök, SV Narayana, A ‘Collagen Hug’ model for
Staphylococcus aureus Cna binding to collagen, 24(24), 4224-4236, 2005 (142).

11

Figure 1-3. Domain organization of the Sdr proteins. (A) ClfA: Clumping factor A; (B)
Clumping factor B; (C) SdrC: SD repeat protein C; (D) SdrD: SD repeat protein D; (E) SdrE:
SD repeat protein E; (F) Bbp: Bone sialoprotein-binding protein. S: signal sequence; A:
amino terminal A domain; B: B-repeats; R: SD repeat region; M: membrane spanning region.
Green: proline-rich region; Red: EF-hands; Blue: TYTFTDYVD. Adapted from Trends in
Microbiology, 6 (12), TJ Foster and M Hook, Surface protein adhesins of Staphylococcus
aureus, 484-488, 1998, with permission from Elsevier Limited (39).
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peptide has been solved (43) (25). ClfA and ClfB recognize different Fg chains: γ and α,
respectively (43) (131) .
ClfA is considered to be the principal protein contributing to clumping by binding to
fibrin clots. Moreover, it has been shown to play a role in a rat endocarditis model of
infection (30), and enriched pooled immunoglobulins against ClfA had therapeutic effects
against a catheter-induced aortic valve infective endocarditis rabbit model. (130). ClfA can
interfere with Factor XIII mediated fibrin formation (79).

In addition, ClfA binds to

complement regulator factor I, which increases cleavage of the complement protein C3b
(54). ClfB also binds to cytokeratin 10 and plays a role in binding to nasal epithelial cells
(134) (132).

SdrG
SdrG is a Fg-binding MSCRAMM of S. epidermidis.

SdrG is discussed here

because its structure and binding mechanism may closely mimic that of S. aureus
MSCRAMMs discussed in detail throughout these studies. It targets the thrombin cleavage
site of the Bβ chain, and inhibits the release of fibrinopeptides B, which, in turn, inhibits the
formation of fibrin (22). Its ligand-binding trench lies between the N2 and N3 domains.
The structures of apo-SdrGN2N3 and of the complex formed by SdrGN2N3 with a
peptide corresponding to the Bβ chain residues 6-20 were solved to determine the binding
mechanism. The co-crystal structure shows that the peptide binds to a trench between the
two immunoglobulin-like N2 and N3 domains (Figure 1-4) (102). In the dock, lock, and latch
(DLL) mechanism, the Fg peptide docks into the ligand-binding trench formed between the
N2 and N3 domains of SdrGN2N3. Next, the peptide is locked by a redirection of residues in
the C-terminus of N3, which ultimately form a latch that holds the peptide in the ligandbinding trench by forming a β-strand by complementation (102) (10).
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Figure 1-4. See next page for legend.
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Figure 1-4. Previous page. Structural representation of the dock, lock, and latch model
(A) Domain organization of SdrG. (B) Structure of SdrGN2N3. Yellow: N2, green: N3, red
wavy line: lock and latch residues. 1) Open, unbound protein; 2) Ligand (purple) docks
into the ligand binding trench; 3) The lock residues are redirected by ligand; 4) The latch
forms a β-strand with the N2 domain holding the ligand in place. (C) Models for 1)
permanently open SdrG(S483C,P595C) and 2) permanently closed SdrG(E381C,
P595C). Inset: zoom view of the disulfide bond that covalently closes N2N3. Printed with
permission from Journal of Biological Chemistry for nonprofit/noncommercial use : MG
Bowden, AP Heuck, K Ponnuraj, E Kolosova, D Choe, S Gurusiddappa, SVL Narayana
AE Johnson, and M Hook, Evidence for the “Dock, Lock, and Latch” Ligand Binding
Mechanism of the Staphylococcal Microbial Surface Component Recognizing Adhesive
Matrix Molecules (MSCRAMM) SdrG, 283, 638-647, 2008 (10).

Figure 1-5. Below. Cartoon representation of the binding between SdrG and fibrinogen.
(A) The N2 and N3 regions are in open conformation without ligand and the B-repeats
are extended. (B) The Fg peptide (red) is bound and the N2N3 domains are closed; the
B repeats are compact due to the redirection of the latching residues. Printed with
permission from Journal of Biological Chemistry for nonprofit/noncommercial use : MG
Bowden, AP Heuck, K Ponnuraj, E Kolosova, D Choe, S Gurusiddappa, SVL Narayana
AE Johnson, and M Hook, Evidence for the “Dock, Lock, and Latch” Ligand Binding
Mechanism of the Staphylococcal Microbial Surface Component Recognizing Adhesive
Matrix Molecules (MSCRAMM) SdrG, 283, 638-647, 2008 (10).
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To biochemically support the findings, further experiments were performed using
SdrGN2N3 mutants (10). The apo form of SdrGN2N3 has an available ligand trench, and a
flexible N3 extension, or latch, this form is referred to as “open.” However, in the proteinpeptide complex the N3 extending residues have been redirected to cover the ligand
pocket; this form of the protein is referred to as “closed.”

Therefore, mutations were

introduced to force the protein to exist in either the open or closed conformations (Figure 15). Binding and Forster resonance energy transfer experiments confirmed that the peptide
can only bind to an open conformation that closes after ligand binding (Figure 1-5) (10).
Because the Sdr proteins are similar in domain organization and folding, the dock, lock, and
latch mechanism of binding has been proposed for the Sdr family of MSCRAMMs

Bbp
Studies with S. aureus strains that cause osteomyelitis led to the discovery that the
bacteria bind to bone-sialoprotein (BSP) (110). Biochemical studies were used to attribute
BSP binding to the determinant, bone-sialoprotein-binding protein (Bbp) (138). The binding
residues were mapped to the amino-terminus of BSP. Bbp is an MSCRAMM in the Sdr
sub-family; therefore, it shares similarities with the clumping factors and SdrG. Bbp has the
conserved TYTFTDYVD motif in the A domain and three B-repeats. Antibody titers to Bbp
are high in diabetic osteomyelitis patients.

Clinically, anti-Bbp sera may be used to

differentiate cases of osteomyelitis from soft tissue infections (101).

Fg - a common MSCRAMM target
Fibrinogen (Fg) is a 340 kDa dimeric glycoprotein composed of two sets of three
polypeptides, Aα, Bβ, and γ that are covalently linked by disulfide bonds (Figure 1-6). The
central region of the dimer contains the amino-termini of the chains. Following the central
domain is a coiled-coil region. The ends of the dimer are globular, and the Aα chain forms
16

Figure 1-6. Structure of fibrinogen. (A) Individual Fg chains, Aα, (blue) Bβ (green) and
γ (red), FpA and FpB: fibrinopeptides A and B; black bars: disulfide bonds; triple
arrows: plasmin cleavage sites for D and E fragments; single arrows: cleavage sites
for removal of αC and BβN regions. (B) Crystal structure of fibrinogen. (C) Fibrinogen
structure and other regions not crystallized: the αC-domains; αC-connectors; the
amino-terminus of Bβ (BβN) displayed with random conformations; the A, B, and P
domains of the D region; the holes and nodules are asterisked. Reprinted from
Journal of Thrombosis and Haemostasis 7, 355-359, L Medved and JW Weisel,
Recommendations for nomenclature on fibrinogen and fibrin, 2009 with permission
from John Wiley and Sons (88).
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a hairpin that directs its carboxy-terminus away from the ends of the dimer towards the
central region (Figure 1-6). Crystallographic studies have elucidated the structure of Fg;
however the carboxy-terminus of the Aα chain (αC) has not been crystallized with the rest
of the molecule (67) (139). Instead, part of the αC structure has been solved with nuclear
magnetic resonance using smaller constructs (17) (128).
Hepatocytes synthesize 1.7-5 grams of Fg per day. Approximately 75% of the Fg is
found in the plasma, while the rest is in the interstitium and lymph (123). Evidence of nonhepatocyte synthesis also exists (76). In addition, platelets may endocytose Fg, as it has
been found in the α granules (56) (55).
The major role of Fg is to form fibrin clots. During the clotting cascade, prothrombin
is activated, and thrombin cleaves fibrinopeptide A from the amino-terminus of the Aα
chain, which exposes the ‘a’ knobs. The result is a fibrin monomer that binds to other fibrin
monomers to form fibrin protofibrils (91). Next, thrombin cleaves fibrinopeptide B from the
amino-terminus of the Bβ chain, exposing the ‘b’ knobs (140). The protofibrils associate
with each other to form fibrin fibers. Factor XIIIa is a transglutaminase that catalyzes the
formation of covalent bonds between the α and γ chains, this crosslinks the fibrin fibrils
(116), forming an insoluble meshwork. Plasmin cleavage can degrade fibrin into one E and
two D fragments (88).
Fg possesses a multitude of biological functions involving interactions with other
proteins and cells in addition to its coagulation function.

The β chain mediates the

interaction between fibrin and heparin (97). Moreover, it can bind to endothelial cells via
vascular endothelial-cadherin (5).

Fibrinogen contains three arginine-glycine-aspartate

(RGD) sites: two in the Aα chain and one in the γ chain, that interact with α5β1, αvβ3, and
αIIbβ3 integrins on endothelial cells, fibroblasts, and platelets (119) (42) (3). In addition,
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fibrinogen can bind to leukocytes via αMβ2 (36). The Aα chain can also bind to fibronectin
(84).

MSCRAMM-mediated platelet activation
MSCRAMMs bind to platelets leading to activation and aggregation.

In the

presence of fibrinogen, platelet binding is enhanced (34) (Figure 1-7). The Fnbps use
fibrinogen and fibronectin bridges with the platelet integrin αIIbβ3 to activate platelets.
Furthermore, the activation may occur via bridging FcγRIIa on platelets with antibodies
specific for Fnbps (35). Also, Protein A, ClfA, ClfB, and SdrE all bind to platelets causing
their aggregation (96). Although no ligand has been reported for SdrE, its ability to bind to
platelets was dependent upon the presence of an unknown plasma protein. Protein A can
activate platelets via a direct interaction or through an immunoglobulin bridge to surface Fc
receptors (96).
Surface anchored proteins contribute to the pathogenesis and survival of S. aureus
in host tissues and blood. By binding to extracellular proteins, MSCRAMMs may mediate a
stealth form and help the bacterium hide from host defense mechanisms, which they
accomplish by coating the bacterial surface with host proteins or by invasion into host cells.

Toxins
Toxins are secreted bacterial proteins whose activities lead to host cell death.
Targets have been identified for many staphylococcal toxins, and some are associated with
a specific disease manifestation.
The α-, β-, γ-, and δ-hemolysins, leukocidin, and Panton-Valentine leukocidin (PVL)
may all be encoded by a particular S. aureus strain. The α- and γ-hemolysins, leukocidin
and PVL are part of the pore-forming toxin family. The α-toxin, or α-hemolysin (α-HL), has
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Figure 1-7. Staphylococccus aureus platelet activation. (A) Rapid platelet activation occurs via a fibrinogen bridge of
FnbpA or ClfA and the platelet integrin αIIbβ3 with a protein-specific Immunoglobulin G (IgG) which binds to the
FcγRIIa. (B) Rapid platelet activation occurs via a fibronectin bridge of FnbpA and the platelet integrin GPIIb/IIIa with
a protein-specific IgG which binds to the FcγRIIa. (C) Slow platelet activation occurs when protein specific IgG binds
to both the protein and to FcγRIIa, leading to the classical pathway of complement activation. Reprinted by
permission from Macmillan Publishers Ltd: Nature Reviews Microbiology, JR Fitzgerald, TJ Foster, D Cox, The
interaction of bacterial pathogens with platelets, 4(6), 445-457, 2006 (34).

been widely studied. It inserts into the host cell membrane as a heptamer, and forms βbarrel pores on the surface. Multiple pores on the cell surface can lead to cell death.
Virulence conferred by α-HL has been implicated in many models of staphylococcal
disease including mastitis, pneumonia, and subcutaneous lesions (11) (98) (16). In addition
to red-blood cells, the toxin also targets immune and epithelial cells. Additionally, β-toxin is
a sphingomyelinase that has been implicated in a mammary gland infection model (11).
The δ-hemolysin is a small cytolysin and phenol-soluble modulin that can insert into the
membrane of host cells (33). PVL, γ-hemolysin and leukocidin are bi-component toxins that
require both subunits to bind to their target cells. The S. aureus hlg locus encodes three
proteins:

HlgA, HlgB, and HlgC.

The HlgA-HlgB combination forms the hemolysin;

whereas, the HlgB-HlgC combination forms leukocidin.

The γ-hemolysin has been

implicated in a rabbit endophthalmitis model of infection (121).

PVL is specific for

polymorphonuclear cells, monocytes, and macrophages, and its two components are LukSPV and LukF-PV. CA-MRSA strains including the predominant clone, USA300, produce
this toxin (125). These cytotoxins can target many cell types and have been implicated in
various S. aureus diseases.
The staphylococcal enterotoxins (SE) and toxic shock syndrome toxin (TSST-1) are
pyrogenic toxin superantigens (PTSAgs) and have been directly implicated in virulence.
They bind to human major histocompatibility complex class II (MHCII) and T cell receptors
(TCR) forming a crosslink between the two proteins.

This interaction leads to T cell

proliferation and release of cytokines causing an overwhelming inflammatory response in
the host (90) (62).

PTSAgs induce expansion of T cells specific for the TCRβ-chain

variable region (109). TSST-1 and some SEs also cause vomiting. Staphylococcal food
poisoning is attributed to the SEs, and it has been hypothesized that this is due to
inflammation in the gastrointestinal tract caused by localized SE emetic reflex (63). TSST-1

21

is considered as the cause of all menstruation-related TSS.

TSST-1 permeates and

crosses the vaginal mucosa, explaining why patients do not appear bacteremic when
suffering from menstruation-related TSS.

Crystallographic data has been used to

determine the interacting residues between PTSAgs and their targets. Depending on their
exact location within the molecule, mutations in the TCR or MHCII binding residues may
diminish or enhance activity or the PTSAgs (77).

Other virulence factors used for immune evasion
Phagocytosis is a major mechanism of host defense against bacteria. S. aureus
strains possess a capsule composed of polysaccharide.

Strains with serotypes 5 and 8

show increased virulence in bacteremia, septicemia, and endocarditis (126), (95), (6). The
enhanced virulence conferred by the capsule is due to its ability to decrease the uptake of
bacteria by opsonophagocytosis (126).

Also, pretreatment with antibodies against the

capsule is protective in endocarditis (74).
Some staphylococcal proteins target the host complement pathway.

The

complement system is composed of proteins that are cleaved and activated to coat the
bacteria and form a membrane attack complex. The extracellular fibrinogen-binding protein
(Efb), the Staphylococcus complement inhibitor (SCIN), and staphylokinase (SAK) aid S.
aureus in evasion by interfering with the action of serum complement proteins (108). Efb is
able to bind to complement factor 3 (C3), thereby inhibiting the ability of C3 to coat the
bacteria (75). SCIN inhibits C3b formation by binding to the C3 convertases, C4bC2a of
the classical pathway and C3bBb of the alternative pathway, (108), thereby inhibiting
bacterial phagocytosis and neutrophil killing. SAK activates plasminogen, which leads to its
cleavage of the C3b and IgG that may coat the surfaces of bacteria and inhibit
opsonophagocytosis (108).

22

Neutrophil recruitment is targeted by the chemotaxis inhibitory protein of
staphylococci (CHIPS) and the extracellular adherence protein (Eap; also known as MHCII
analogue protein, MAP). These are secreted proteins that can bind to two targets leading
to immune evasion. First, the ability of neutrophils to migrate to the site of infection is
inhibited by CHIPS binding to the formyl peptide receptor via the amino terminus of CHIPS
(103).

Also, by binding to the complement factor 5a receptor, CHIPS inhibits the

chemoattractant C5a from binding to its receptor. Eap can bind to intercellular adhesion
molecule-1 (ICAM-1), a ligand for the integrin lymphocyte-function-associated antigen (LFA1), which is needed for neutrophil adhesion and, ultimately, extravasation (19).

Staphylococcal vaccine efforts
Undoubtedly, the need for a vaccine for S. aureus is dire due to the increased
number of infections caused by antibiotic resistant strains.

Clinical and basic science

research on S. aureus has provided the biomedical community with vast amounts of
knowledge to understand the pathogenesis of S. aureus infections, but generating a
vaccine for S. aureus is complicated. First, the bacterium has many virulence factors with
redundant activities. Second, the diseases caused by S. aureus are varied. Furthermore, a
significant proportion of the population is composed of asymptomatic carriers that may not
develop disease. Due to their impaired immune status, immunocompromised individuals
and those at elevated risk for infection, would be optimal candidates for passive
immunization therapy. Active immunization would be ideal for individuals with the ability to
mount an immune response, like healthcare workers.

These factors pose a major

challenge in deciphering how to best construct a vaccine.
Recently,

pharmaceutical

companies

have

immunization programs (Summarized in Table 1-1).

conducted

active

and

passive

Nabi developed StaphVAX, which

contains capsular antigens, and tested its efficacy in dialysis patients. Although, StaphVAX
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Table 1-1. Staphylococcus aureus vaccines in clinical trials. Reprinted from Infectious
Disease Clinics of North America, 23 (1), AC Schaffer and JC Lee, Staphylococcal
vaccines and immunotherapies, 153-171, 2009, with permission from Elsevier Limited
(112).
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failed phase III trials, it did show protection for a brief period of 3-40 weeks post-vaccination
(114). Additionally, the antibodies in Nabi’s AltaStaph vaccine were generated in subjects
who had been immunized with StaphVax, and these were termed AltaStaph. AltaStaph
failed phase II trials on bacteremic patients. Merck’s V710 vaccine is composed of IsdB
and has successfully undergone phase I testing (112).

Inhibitex had two anti-ClfA

preparations; Veronate was an IVIg that failed a phase III trial in neonates, and Aurexis was
a humanized monoclonal with a successful phase II trial of bacteremic patients.
Pagibaximab (BSYX-A110) by Biosynexus is a chimeric monoclonal against lipoteichoic
acid that reduced the rate of developing bacteremia in neonates (133).

Despite these

efforts, a vaccine has not been approved by the FDA.
Preclinical studies have shown promise in developing vaccines against S. aureus
infections targeted at toxins and surface components. A tetravalent vaccine composed of
SdrD, SdrE, IsdA, and IsdB was tested in a murine kidney abscess model, and mice
immunized with the four components survived challenge with clinical isolates (118). This
approach is promising, as a vaccine against S. aureus may need to target multiple epitopes
or proteins. Efforts to target the α-HL have also shown success preclinically. Antibodies
generated to an inactive α-HL mutant (89) protected mice challenged with a lethal dose of
clinical isolates in a pneumonia model (15). Furthermore, the mice had less inflammation,
decreased bacterial burden, and less tissue destruction (15) (14). These animal studies
have helped to elucidate potential vaccine candidates by discerning the benefit of
antibodies against particular virulence factors.

Summary
Antibiotics are the current treatment for S. aureus infections. With every wave of
antibiotic resistance, the medical community has to adapt by using last line of defense
antibiotics or by combining multiple antibiotics in order to clear the infections.
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MRSA infections on the rise, there is a need to abrogate the spread of infections. Although
the search for vaccine candidates has resulted in mixed successes, past attempts at S.
aureus vaccines have indicated that staphylococcal virulence factors can elicit a protective
response. By identifying and characterizing the events that occur between the bacteria and
the infected host, valuable information can be gained about pathogenesis. This knowledge
can then be used to develop disease models where the specific virulence factor’s
contribution can be analyzed. Also, these types of experiments have helped us to identify
redundant functions of bacterial proteins. Conducting epidemiological studies may identify
correlations between a particular disease and a virulence factor. These studies may serve
as guides to identify functions. Ultimately, the virulence factors can be examined to link the
epidemiologically associated factor with specific disease models.
In this study, a surface and a secreted factor of S. aureus were examined. First, I
examined function of a secreted leukotoxin whose presence was associated with strains
that cause necrotizing pneumonia.
determine its role in disease.

In vitro and in vivo analyses were performed to
Secondly, an MSCRAMM that is implicated in

hematogeneous osteomyelitis was studied. Through biochemical and biophysical assays, I
identified a novel ligand for the adhesin. By dissecting the interaction with its ligand, I
discovered its potential ability to abrogate host coagulation.
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CHAPTER II
Panton-Valentine Leukocidin causes necrotizing pneumonia

Introduction
Analysis of CA-MRSA strains has revealed the presence of the Panton-Valentine
leukocidin (PVL) (78) (46).

PVL is a secreted toxin that is composed of two protein

subunits, LukS-PV and LukF-PV, that act synergistically to form pores in the membranes of
host monocytes, macrophages, and polymorphonuclear cells (20).

PVL belongs to the

pore-forming toxin (PFT) family that includes α- and γ-hemolysin. With the exception of αhemolysin, the staphylococcal PFTs contain an S subunit (HlgA, HlgC, LukE, LukS-I, LukM,
and LukS-PV) and an F subunit (HlgB, LukD, LukF-I, LukF’, and LukS-PV) (20). Identity
within the subunit classes is high, ranging from 59-79% and 71-79% for S and F,
respectively, whereas the identity between S and F is only approximately 25% (65) (104).
Alpha-hemolysin most resembles an F monomer and is the prototypical PFT. Although the
sequence identities between PVL and other PFTs are high, PVL is not hemolytic (104) (20).
Recently, the presence of PVL has been linked to S. aureus strains isolated from
necrotizing pneumonia patients (78) (46).

Necrotizing pneumonia is characterized by

massive cell infiltration, severe tissue destruction, and hemorrhage in the air space.
Etienne and colleagues conducted a study where they discovered that infection by PVLpositive strains were more common among young, immunocompetent patients (46). These
strains caused a fast onset of infection with a high lethality rate. The authors also analyzed
lung sections from PVL-positive S. aureus necrotizing pneumonia patients and showed
overwhelming inflammation in the lungs, as well as the presence of PVL (28, 45). However,
it is not known whether PVL is the direct cause for the increased severity of symptoms
observed in these patients.
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Neutrophils are often the first cells to respond at the site of infection (44). They are
recruited by chemoattractive factors like chemokines, such as interleukin-8 (IL-8), and other
soluble substances, like leukotrienes and platelet activating factor (106) (135). IL-8 is a
chemokine produced and secreted by immune and epithelial cells after activation with
bacterial determinants or inflammatory cytokines; after secretion, it may last for several
days.

Increased levels of IL-8 have been shown in bronchial lavages of pneumonia

patients (106) (107).

In addition to its pore-forming activity, PVL exposure causes

leukocytes to secrete inflammatory mediators (69). After PVL treatment, leukocytes have
been shown to release IL-8, hexosaminidase, lysozyme, β-glucuronidase, IL-8, Leukotriene
B4, and histamine (70) (20) (137) (68) (58).
The significance of PVL in CA-MRSA and necrotizing pneumonia S. aureus strains
was addressed in this study. We sought to determine whether PVL plays a pivotal role in
the inflammation observed in necrotizing pneumonia. Specifically, we tested the ability of
PVL to cause inflammation in lung epithelial cells in vitro and to cause necrotizing
pneumonia in a mouse model.
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Materials and Methods

Generation and purification of PVL subunits- In order to generate highly active PVL, each
subunit was expressed separately, under the control of the native PVL promoter. The
plasmids (kindly donated by Francois Vandenesch) were transformed into S. aureus 8325-4
that was engineered with deletions of hla, hlb, and hlg (kindly donated by Timothy Foster) in
order to decrease the chance of contamination by other PFTs. The secreted PVL subunits
were purified as previously described (104) using cation-exchange chromatography.

Rabbit hemolysis assay- Rabbit erythrocytes (kindly provided by Steven Norris) were
washed and resuspended in PBS. A 1% solution of rabbit erythrocyes was incubated with
increasing concentrations (1-100 nM) of LukS-PV, LukF-PV, or PVL for 60 minutes at 37°C.
The samples were subjected to centrifugation and the absorbance of the supernatant was
measured at 525 nm.

Assessment of protein activity- LukS-PV binding to isolated human neutrophils was
performed using flow cytometry. A three-color assay was developed that allowed us to
verify that the neutrophils were pure and that LukS-PV was binding to this population of
cells. Neutrophils were incubated with LukS-PV followed by incubation with anti-LukS-PV
monoclonal antibody conjugated to PE-Cy5.5 (Nabi).

In order to detect the neutrophil

population, the cells were stained with anti-CD11b-PE and anti-CD15-FITC (R&D Systems).
Furthermore, we tested the purified subunits for leukotoxic activity. Briefly, neutrophils were
incubated with increasing concentrations (0.1-30 nM) of PVL, followed by incubation with 2(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) (Roche), a
tetrazolium salt used for viability determination (124). The absorbance was measured with
a Thermo Max plate reader at 650 nm with reference subtraction at 450 nm.
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IL-8 production by PVL treated epithelial cells- IL-8 induction from PVL-treated epithelial
cells was measured. Briefly, A549 cells were seeded overnight, washed, and incubated
with PBS, PVL (1 nM) , or LPS (100 ng/ml) for 24 hours. The cells were washed, RNA was
extracted and reverse transcriptase PCR was performed to detect expression of IL-8. The
primers

used

were

5’-AGCTCTGTGTGAAGGTGCAG-3’

and

5’-

ATTTCTGTGTTGGCGCAGT-3’ for IL-8 and 5’-CCAGGTCTCCTCTGACT-3’ and 5’TGCTGTAGCCAAATTCGTTG-3’ for GAPDH, as a control.

Furthermore, secreted IL-8

was measured from cell-conditioned media using the eBioscience IL-8 sandwich ELISA kit.
Briefly, A549 cells were seeded overnight, washed, and incubated with PBS, LPS (100
ng/ml), or increasing concentrations of PVL (10 nM – 10 µM) for 4 hours.

The cell-

conditioned medium was pipetted and debris was pelleted by centrifugation. All incubations
were conducted as recommended by the manufacturer.

Pro-inflammatory protein array screen- In order to determine if PVL could induce secretion
of many pro-inflammatory cytokines, a Panomics protein array was incubated with cellconditioned media from PVL-treated lung epithelial cells. Briefly, A549 cells were seeded
overnight, washed, and incubated with 30 nM PVL for 24 hours.

The cell-conditioned

medium was pipetted, and debris was pelleted by centrifugation. All incubations were
performed according to manufacturer’s instructions.
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Results

Active PVL subunits were produced.
The purity of PVL subunits was confirmed by SDS-PAGE, and Western blotting
(Figure 2-1a).

Rabbit erythrocytes were incubated with increasing concentrations of

purified LukS-PV, Luk-PV, or PVL to assess whether the toxin preparation was
contaminated with other PFTs (Figure 2-1b). The results confirmed the purity of the PVL
preparation. Next, the toxin’s activity on isolated human neutrophils was examined. Flow
cytometry binding experiments confirmed that the LukS-PV subunit bound to CD15 and
CD11b double positive cells (Figure 2-1c).

Furthermore, PVL readily lysed human

neutrophils, with an LD50 of 250 pM (Figure 2-1d).

PVL-induced inflammation from lung epithelial cells
To determine if PVL production by pneumonia-causing S. aureus strains triggered
inflammatory responses from lung epithelial cells, experiments were performed using in
vitro cultured A549 cells. The ability of PVL to stimulate IL-8 production in A549 cells was
examined. The cells were incubated with PVL or LPS, as a positive control, followed by
detection of IL-8 expression using RT-PCR (Figure 2-2a). The PVL-treated epithelial cells
produced approximately the same amount of IL-8 as the LPS-treated cells, and untreated
cells did not produce IL-8, indicating that PVL induced expression of the proinflammatory
cytokine. Next, the ability of PVL to induce secretion of IL-8 by A549 cells was examined.
The cells were incubated with PBS, LPS, or increasing concentrations of PVL (10 nM- 10
µM), and the cell-conditioned media was harvested. The concentration of secreted IL-8
was measured using a sandwich ELISA.

Results showed that PVL-treated A549 cells

secreted similar amounts of IL-8 as that secreted by LPS-stimulated cells (Figure 2-2b).
Together, these data indicate that PVL-stimulated A549 cells express and secrete IL-8.
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Figure 2-1. The purified Panton-Valentine Leukocidin subunits are active. (A) Western
blots: The LukF-PV (left) and LukS-PV (right) proteins were separated by SDS-PAGE and
immunoblotted with protein-specific monoclonal antibodies followed by goat-anti-mouse
IgG. (B) Hemolysis assay: Rabbit erythrocytes were suspended in PBS and incubated
with increasing concentrations (1-100 nM) of LukS-PV, LukF-PV, or both subunits for 30
minutes. Erythrocytes treated with water served as a positive control, and for normalization.
(C) Flow cytometry: Isolated human neutrophils were incubated with 0.5 nM LukS-PV
followed by anti-LukS-PV conjugated to Pe-Cy5.5, anti-CD15-FITC, and anti-CD11b-PE.
Top panels are controls of the bottom panels. (D) Neutrophil viability assay: Isolated
human neutrophils were incubated with increasing concentrations (1-100 nM) of LukS-PV,
LukF-PV, or both subunits prior to the addition of WST-1 for viability determination.
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Figure 2-2. PVL-induced inflammatory cytokine secretion
from alveolar epithelial cells.
(A) Induction of IL-8
expression measured by Reverse-transcriptase PCR: Lung
epithelial cells were incubated with PVL, LPS, or untreated
followed by RNA extraction and RT-PCR with primers for
IL-8 or GAPDH. (B) Induction of IL-8 secretion by lung
epithelial cells. Cells were incubated with PBS, LPS, or
increasing concentrations (10 nM -10 µM) of LukS-PV,
LukF-PV, or both subunits. The IL-8 concentrations of cellconditioned medium were determined by sandwich ELISA.
(C) Panomics inflammatory cytokine protein array:
Induction of inflammatory cytokine secretion from PVLtreated lung epithelial cells was determined by incubating
the array membranes with cell-conditioned medium.
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To determine if PVL induced the secretion of additional pro-inflammatory mediators,
a Panomics protein array was used. A549 cells were treated with PVL and cell-conditioned
media were collected and used for protein array incubation (Figure 2-2c). The secretion
profiles of PVL and control cells were compared. PVL-treated epithelial cells secreted IL-8,
the Th2-promoting cytokine IL-4, and the Th1-promoting cytokines IL-12 and Leptin (in
lesser quantity).

However, PVL failed to induce secretion of eotaxin, IP-10, Rantes,

granulocyte-monocyte colony stimulating factor, tumor necrosis factor-α, IL-1, IL-3, IL-6, IL10, IL-17, MIP-1, and MIP-5. These results confirmed the secretion of IL-8, and identified
the ability of PVL to induce secretion of additional cytokines from A549 cells.

PVL-induced necrotizing pneumonia and active immunization in a murine pneumonia
model
An acute mouse model of pneumonia was developed and used to determine if
instillation with PVL causes pneumonia. In this model, LukS-PV by itself did not cause
pneumonia, presumably because both of the toxin subunits are required for its pore-forming
activity.

However, instilling both PVL components resulted in pathology that was

comparable to that observed in PVL-positive S. aureus infected animals, and PVL-negative
S. aureus caused minor inflammation (71) (Figure 2-3). The PVL-instilled mice had severe
inflammation, vascular leakage, and disrupted alveolar structure. Additionally, 70% of mice
instilled with 10 µg of protein died within 24 hours. These results indicate that both PVL
subunits are required to cause necrotizing pneumonia. PVL by itself is sufficient to cause
lethality in mice and both subunits are required for the toxicity.
Further studies evaluated the PVL subunits as vaccinogens. Mice were immunized
with either PVL subunit and subsequently challenged with a lethal dose of the virulent S.
aureus USA300 strain (Figure 2-4) (13). Active immunization with LukS-PV resulted in
survival of 75% of the mice challenged; whereas 50% of mice immunized with LukF-PV or
35

Figure 2-3. PVL expression enhances the virulence of isogenic S. aureus strains. (A, B, E, F,
I, and J) Lung histology of mice infected with PVL-positive and PVL-negative strains or
inoculated with PVL toxin. The sections are representative of at least three separate
experiments. Scale bar, 100 µm. (C, G, and K) Line graphs indicate weight loss in grams. (C)
Parental versus PVL phage; *P < 0.001. (G) Parental versus PVL phage; no statistical
difference observed. (K) Animals inoculated with 3 µg of LukS+F-PV versus 5 µg LukS-PV;
*P < 0.01 on day 1. (D, H, and L) Mouse survival. (D) Parental and PVL plasmid; (H) PVL
phage, PVL phage, and PVL phage PVL plasmid; (L) 20 µg or 10 µg of LukS+LukF-PV
versus 3 µg LukS+LukF-PV or 5 µg LukS-PV, *P <0.0001. Reprinted from Science 315
(5815), The Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing
Pneumonia, M Labandeira-Rey, FCouzon, S Boisset, EL. Brown, M Bes, Y Benito, EM
Barbu, V Vazquez, M Hook, J Etienne, F Vandenesch, MG Bowden, 2007, with permission
from the American Association for the Advancement of Science (71).
[Full Reference Citation]. Reprinted with permission from AAAS..
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Figure 2-4. Percent survival following intranasal inoculation with Staphylococcus aureus
USA300. Balb/c mice (total numbers used/group indicated in parentheses) were
vaccinated subcutaneously with recombinant LukF, LukS, control proteins or adjuvant
alone prior to infection with 5 × 107 CFUs of S. aureus in a volume of 20 µL. Mouse
survival was monitored for up to 7 days post-infection.
Reprinted from Clinical
Microbiology and Infection 15(2), 156-164, EL Brown, O Dumitrescu, D Thomas, C
Badiou, EM Koers, P Choudhury, V Vazquez, J Etienne, G Lina, F Vandenesch, and MG
Bowden, The Panton-Valentine leukocidin vaccine protects mice against lung and skin
infections caused by Staphylococcus aureus USA300, 2008 with permission from John
Wiley and Sons (13).
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α-HL survived the infection. These results indicate that the PVL subunits can generate a
protective response against lethal challenge by PVL-producing S. aureus in a pneumonia
model.
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Discussion
Due to the increased numbers of MRSA cases, many epidemiological studies have
been conducted to identify correlations between the presence of potential virulence factors
with S. aureus-caused diseases. The pvl genes have been detected in strains that cause
severe necrotizing pneumonia.

Therefore, we sought to determine whether we could

experimentally link the presence of PVL in these strains to the severity of disease.
In order to study the toxin, recombinant subunits LukS-PV and LukF-PV were
generated in a S. aureus strain deficient in the expression of α-, β-, and γ-hemolysins. The
toxin preparation was pure, devoid of other toxins and cell-wall components, and was fully
active towards human neutrophils.

Prior to conducting mouse experiments, in vitro

experiments with lung epithelial cells were performed, and I detected IL-8 secretion from
toxin-treated A549 cells. Results from the mouse model have clearly implicated PVL as a
cause of necrotizing pneumonia. An acute model of pneumonia was used to compare the
virulence of PVL-positive versus PVL-negative strains and PVL protein instillation into the
mice. Indeed, the PVL-positive infected mice developed severe pneumonia; whereas, the
PVL-negative strains caused mild inflammation.

Surprisingly, instilling mice with PVL

protein alone was sufficient to cause necrotizing pneumonia (71).
Furthermore, a vaccine study performed with the PVL subunits showed that mucosal
vaccination with LukS-PV protein was a successful active immunization strategy, as
immunized mice showed higher percentage of survival after challenge with a clinical isolate
than control mice (13).
Results from experiments performed with the recombinant PVL toxin combined its
correlation with strains that cause necrotizing pneumonia. Necrotizing pneumonia causes
lung tissue destruction, vascular leakage, and overwhelming inflammation.

In vitro

experiments conducted with epithelial cells treated with each subunit or both resulted in the
release of IL-8 from epithelial cells.
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However, the overwhelming inflammation seen during necrotizing pneumonia
cannot be solely attributed to PVL-induced IL-8 secretion from airway epithelial cells.
Instead, the PVL-induced pneumonia was only observed in mice instilled with both PVL
subunits, suggesting that the toxin’s ability to cause pneumonia may be related to its ability
to lyse leukocytes. Therefore, the pneumonia is likely due to the toxin’s high activity on
infiltrating neutrophils and resident alveolar macrophages, and its ability to cause epithelial
cell inflammation is less of a factor. To test the contribution of leukocyte inflammation, the
experiments described herein could be performed on leukocyte-depleted animals. Previous
efforts to conduct these experiments resulted in morbidity and mortality of all animals,
whether infected with PVL-negative or PVL-positive S. aureus, because the leukopenia
rendered them more susceptible to staphylococcal disease.
In conclusion, virulence factors that are correlated epidemiologically with specific
disease can be studied in vitro and in vivo to link the presence of genes with disease
causation.
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CHAPTER III
The MSCRAMM Bbp targets the Fibrinogen Aα chain
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CHAPTER III
The MSCRAMM Bbp targets the Fibrinogen Aα chain

Introduction
S. aureus possesses cell-surface adhesins to aid in the attachment, colonization,
and invasion of host tissues. The bacteria may also use adhesins or Microbial Surface
Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) to evade host immune
responses. MSCRAMMs can target both extracellular matrix and blood plasma molecules
and several MSCRAMMs have more than one ligand (Table 3-1).
The domain organization and predicted structures of the Sdr subset of the
MSCRAMMs are similar, although sequence identity among the Sdr proteins may be low.
One difference among the Sdr proteins is the B-repeat content. The clumping factors do
not contain B-repeats, while SdrC has two, SdrD has five, and SdrE and Bbp have three.
Also, SdrE and Bbp have been described as allelic variants with higher identity between
these two than among any of the other Sdr proteins. Many studies have correlated the
presence of the Sdr proteins in S. aureus isolated from healthy or sick individuals. Analysis
of isolates from carriage strains and strains that cause invasive disease revealed that the
clfA, clfB, and sdrC genes were present in almost all of the isolates, regardless of the
source. However, only 38-56% of isolates contained the genes sdrD, SdrE, and bbp (100).
Interestingly the authors found sdrE in 40% of the carriage isolates and in 56% of the
strains causing invasive disease; this led to the conclusion that sdrE is preferentially
associated with invasive strains (100).
A second study examined the genes encoding for SdrC, SdrD, and SdrE/Bbp in
carriage and invasive isolates (111). The primers used for this study do not differentiate
sdrE from bbp. sdrC was found in all strains; sdrD was associated with MRSA. sdrE/bbp
was present at similar levels in MSSA and MRSA. Furthermore, the authors concluded that
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Table 3-1. Staphylococcus aureus MSCRAMMs with multiple ligands.
MSCRAMM

Ligands

IgG, von Willebrand Factor, TNFα receptor (TNFR), epidermal
Protein A
growth factor receptor (EGFR)

FnbpA

fibronectin, fibrinogen (Fg), elastin

FnbpB

fibronectin, fibrinogen

ClfA

fibrinogen, complement regulator factor I

ClfB

fibrinogen, cytokeratin 10
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both SdrD and SdrE/bbp may be important in osteomyelitis.

Lastly, when Tristan and

colleagues evaluated carriage, endocarditis, and hematogeneous osteomyelitis/arthritis
isolates, they detected bbp (sdrE was not tested) in 21%, 11%, and 38% of the respective
isolates (127). These studies indicate that sdrE and bbp may be present in S. aureus
isolated from carriers and from patients with invasive disease.
Together, these epidemiological data suggest that the disease with which bbp
preferentially associates is osteomyelitis. However, the fact that the isolates in the study by
Tristan and colleagues evaluated hematogeneous osteomyelitis isolates may indicate a role
for Bbp in the blood. Moreover, patients suffering from diabetic osteomyelitis had higher
titers to Bbp than patients with soft-tissue infections (101). Furthermore, Bbp studies have
revealed bone-sialoprotein (BSP), a major constituent of bone, as a ligand for Bbp binding.
Therefore, it is a potential staphylococcal virulence factor. Because several MSCRAMMs
have multiple ligands, I hypothesized that Bbp may recognize other host proteins.
Fibrinogen (Fg) is a blood glycoprotein involved in the clotting cascade and cell
signaling. It is targeted by many MSCRAMMs (Figure 3-1). It is a dimeric protein composed
of two Aα, Bβ, and γ chains that are held together by intra- and inter-chain disulfide bonds.
Additionally, its overall structure has been solved by crystallography; however, the structure
of the carboxy-terminus of the Aα chain has only been partially elucidated (67) (17). In
order to form fibrin, the fibrinopeptides A and B must be cleaved from the amino-terminus of
the Aα and Bβ chains, respectively, to expose sites that are important for the lateral
aggregation of protofibrils. Additionally, the transglutaminase Factor XIIIa catalyzes the
formation of covalent bonds that crosslink the fibrin fibrils.
The remarkable domain organization similarity among Bbp and other staphylococcal
Fg-binding MSCRAMMs prompted further study to determine if a second ligand for Bbp
exists.

A ligand screen revealed that BbpN2N3 recognizes human Fg.

Therefore, I
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conducted a series of experiments that localized the binding to residues on Fg Aα that are
not targeted by other MSCRAMMs.

Bbp on the surface of bacterial cells mediated

attachment to the mapped residues in Fg Aα.

Furthermore, pretreatment of Fg with

BbpN2N3 inhibited the formation of fibrin.

45

Figure 3-1. MSCRAMMs target different sites in the fibrinogen chains. Cartoon of the separate
chains indicating the residues targeted by ClfA (γ 395-411), SdrG (Bβ 6-20), and ClfB (Aα 316-328).
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Materials and Methods

Commercial reagents- Plasminogen, von Willebrand Factor, and fibronectin depleted
human fibrinogen was from Enzyme Research, human fibronectin was from Chemicon,
collagen I from rat tail tendons was from Cultrex R&D, recombinant human collagen III was
from FibroGen. Bovine serum albumin fraction V (BSA) was from Serological Proteins, Inc.
Restriction enzymes and T4 ligase were from New England Biolabs. Isopropyl-beta-Dthiogalactopyranoside (IPTG) was from Gold BioTechnology, Inc. Chromatography media
and anti-His monoclonal antibody were purchased from GE Healthcare unless otherwise
noted. Nitrocellulose membrane, goat-anti-mouse-alkaline phosphatase, goat-anti-rabbitalkaline phosphatase, and goat-anti-rabbit-horseradish peroxidase were purchased from
Bio-Rad. Donkey-anti-goat-horseradish peroxidase was from Applied Biological Materials
Inc. Superblock, used to block solid-phase assay wells, and NBT/BCIP, for developing
western blots were from ThermoFisher. Lysostaphin, Luria broth, SigmaFast OPD, used to
develop solid phase assays, laminin from Engelbreth-Holm-Swarm murine sarcoma
basement membrane, collagen IV from fibroblast and epithelial cell co-culture, goat-antihuman-Fg, bovine neck ligament elastin, and bovine nasal septum collagen II, and
thrombin were from Sigma. Brain-heart-infusion broth (BHIB) was from Remel. M17 media
was purchased from Oxoid. Oligonucleotides were purchased from IDT.

Media and growth conditions– Escherichia coli strain TOP 10 (Invitrogen) was used for
subcloning Fg truncation mutants, and strains XL-1 Blue and XL-10 Gold (Stratagene) were
used for expression of recombinant proteins. E. coli was cultured at 37°C with shaking
(250 rpm) in Luria broth supplemented with kanamycin (50 µg/ml) for TOP 10 or ampicillin
(100 µg/ml) for XL-1 Blue and XL-10 Gold.

Lactococcus lactis was cultured in M17

supplemented with glucose (0.5%) and erythromycin (5 µg/ml) at 30°C. Staphylococcus
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Table 3-2. Oligonucleotides used in this study.
Primer name

Oligonucleotide sequence

pQE30-BbpF

CCCGGATCCGTTGCTTCAAACAATGTTAATGAT

pQE30-BbpR

CCCAAGCTTTTATTCAGGTTTAACAGTACCGTCACC

pQE30-FgAα1F

CGGGATCC GCAGATAGTGGTGAAGGT

pQE30-FgAα1-575R

CGAAGCTTTTAGGAGTCTCCTCTGTTGTAACT

pQE30-FgAα1-560R

CGAAGCTTTTAGTAACTTGAAGATTTACCACG

pCU1-BbpPrF

CGGGATCCGATATAACATACATCAACAT

pCU1-BbpTrR

CGTCTAGAATATTATCGCCTCATATAAG
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aureus strains MRSA 252 and Newman derivatives were cultured at 37°C with shaking
(250 rpm) in Brain-heart-infusion broth (BHIB) supplemented with erythromycin (5 µg/ml),
tetracycline (2 µg/ml), and/or chloramphenicol (10 µg/ml) as needed.

Recombinant BbpN2N3 - The N2N3 region of Bbp was cloned according to previously
described methods (129). Briefly, S. aureus 024 (kindly donated by C. Ryden) genomic
DNA was used to amplify the N2N3 sequence using the primers listed in Table 3-2
corresponding to the N2N3 subdomains of Bbp for digestion with BamHI and HindIII and
ligation into pQE30. The plasmid was transformed into XL-1 Blue and sequenced to verify
its integrity. This construct was generated by Jenny K. Horndahl in our laboratory. E. coliBbpN2N3 was cultured to exponential phase, induced with 200 µM IPTG, and grown for an
additional 3 hours.

The cells were pelleted, lysed, and purification of BbpN2N3 was

accomplished using Ni2+ affinity chromatography as previously described (22) on a HiTrap
Chelating column. Fractions were analyzed by SDS-PAGE, pooled, and dialyzed for anion
exchange-purification using a Q HP Sepharose.

To assess the purity of BbpN2N3, the

protein was run on 10% SDS-PAGE and stained with Coomassie blue or electrotransferred
to nitrocellulose. The membrane was blocked with TBS containing 0.1%Tween-20 (TBST)
and 1% BSA, and was probed with anti-His monoclonal, followed by anti-mouse-AP.
BbpN2N3 was further analyzed by mass spectrometry (not shown).

Anti-N1 monoclonal antibody- Mouse monoclonal antibody 8B7 recognizing the N1
subdomain of the A domain of Bbp was kindly donated by Pietro Speziale.

Rabbit-anti-BbpN2N3 antibodies- Polyclonal antisera to BbpN2N3 were generated in two
rabbits at Rockland Immunochemicals under the Fast Production Protocol.

IgG was

purified using protein A-sepharose (ThermoFisher) affinity chromatography. Next, the IgG
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was cleared for crossreactive binding to Sdr proteins before positive affinity purification on
BbpN2N3 coupled to EZlink beads (ThermoFisher).

Bbp expression from clinical strains- S. aureus clinical isolate MRSA 252 from blood was
obtained from Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). S.
aureus TCH 60 and TCH 959 skin and abscess isolates, respectively, were kindly donated
by Kristina Hulten. To examine the in vitro expression of Bbp in the strains, overnight
cultures were diluted 1:100 into fresh BHIB. Exponential phase cultures were harvested at
an OD600 of 0.55, 0.6, 0.7,0.8, and 0.9. The cell-wall proteins were harvested by lysostaphin
extraction as previously described (21). Subsequently, the proteins were separated on
SDS-PAGE and electrotransferred to nitrocellulose membrane for Western blotting with
monoclonal-anti-N1 and polyclonal anti-BbpN2N3 antibodies.

Protein modeling– The predicted structure of BbpN2N3 was modeled based on the solved
structure of previously crystallized MSCRAMMs (102) (43) using the Ribbons program.
Structural modeling was performed by Dr. Vannakambadi Ganesh in our laboratory.

BbpN2N3 ligand screen– Binding of BbpN2N3 to various extracellular matrix and plasma
proteins was determined using an ELISA-type solid-phase assay. BSA, Fg, fibronectin,
collagen type I-IV, and elastin were coated on microtiter wells at 1 µg per well, and laminin
was coated at 10 µg per well overnight at 4°C in bicarbonate buffer pH 8.3. The next day,
the wells were washed with TBST, blocked and incubated with ten-fold dilutions of BbpN2N3
(0.1-10 µM), followed by rabbit anti-BbpN2N3 and goat-anti-rabbit HRP for detection of bound
BbpN2N3.

The wells were developed with SigmaFast OPD, and the absorbance was

measured at 450 nm with a Thermo Max plate reader (Molecular Devices).
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Fg binding assay – To detect binding of Fg to Bbp, a solid-phase assay was performed.
Microtiter wells were coated with increasing amounts of BbpN2N3 (0.25-2.5 µg) overnight in
bicarbonate buffer pH 8.3. The next day, wells were washed, blocked, probed with soluble
Fg (1 µM) and detected with anti-human Fg followed by anti-goat-HRP. The wells were
developed, and the absorbance was measured at 450 nm.

Fg species screen – Human, mouse (Enzyme Research), cat, dog, cow, sheep, and pig
(Sigma) Fg, were coated on microtiter wells at 10 µg/ml overnight in bicarbonate buffer pH
8.3. The next day, the wells were washed, blocked, and probed with 500 nM BbpN2N3 and
ClfAN2N3 followed by mouse anti-His-HRP. The wells were developed and the absorbance
was measured at 450 nm.

Surface Plasmon Resonance (SPR) – SPR was performed at 25°C on a BIAcore 3000
system (GE Healthcare). Twelve microliters of Fg in 10 mM sodium acetate pH 5.5 (10
µg/ml) was injected onto an activated CM5 chip surface at a flow rate of 5 µl/min.
Approximately 1600 Response Units (RU) of Fg were immobilized via amine coupling. A
second uncoupled flow cell was activated and deactivated to serve as a reference cell for
binding experiments. Increasing concentrations of BbpN2N3 (40 nM-2.56 µM in TBS-0.005%
Tween 20) were injected to determine the kinetics of the interaction between Fg and
BbpN2N3.

The reference cell sensorgrams were subtracted from the experimental cell

sensorgram. BIAevaluation software was used to determine kinetic constants.

Xiaowen

Liang performed these experiments.

SDS-PAGE and Far Western of Reduced Fg- Laemmli sample buffer containing 10 mM
dithiothreitol was added to Fg for SDS-PAGE separation. The gels were either stained with
Coomassie blue or electrotransferred to nitrocellulose for blotting. Briefly, the membranes
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were blocked with TBST containing 1% BSA followed by probing with BbpN2N3 (15 µg/ml),
ClfAN2N3 (15 µg/ml), or SdrGN2N3 (5 µg/ml). The bound proteins were detected with anti-His
monoclonal antibody followed by anti-mouse-AP.

E. coli Fg constructs and C-terminal truncation mutants - E. coli expressing full-length
recombinant His-tagged Fg chains Aα, Bβ, and γ have been previously described (81) (8,
9). Plasmid containing the Fg Aα sequence was used as template to amplify the DNA
corresponding to mature Aα residues 1-575 and 1-560 using the primers listed in Table 3-2.
Selected plasmids were digested, the inserts ligated to pQE30, and the plasmids
transformed into XL-1 Blue cells.

Sequencing was used to verify the integrity of the

plasmids pQE30-Aα1-575 and pQE30-Aα1-560. The proteins were expressed and induced
with 200 µM IPTG as described above for BbpN2N3, purified using Ni2+ affinity
chromatography in the presence of 8M urea (Sigma), and separated on 10% SDS-PAGE or
used for binding assays.

E. coli Fg construct solid-phase assays- Fg, recombinant Fg chains, and Aα truncation
mutants were coated on microtiter wells in bicarbonate buffer overnight. The wells were
washed, blocked, probed with BbpN2N3 (15.6-500 nM) and detected with anti-BbpN2N3 and
anti-rabbit-HRP. The wells were developed and the absorbance was measured at 450 nm.

E. coli Fg construct Far Westerns- Laemmli sample buffer containing 10 mM dithiothreitol
was added to recombinant Fg constructs and truncation mutants for SDS-PAGE separation
followed by staining with Coomassie blue or transferring to nitrocellulose. The membranes
were blocked with 1% BSA and probed with BbpN2N3 (15 µg/ml) followed by detection with
anti-BbpN2N3 and anti-rabbit-AP.
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Table 3-3. Constructs used in this study.
CONSTRUCT

VECTOR

RESIDUES

SOURCE

E. coli BbpN2N3

pQE30

270-599

This study

E. coli SdrGN2N3

pQE30

273-597

(102)

E. coli ClfAN2N3

pQE30

229-545

(43)

Full length mature
E. coli Fg Aα

pQE30

(81)
Aα

E. coli Fg Aα1-575

pQE30

1-575 of mature Aα

This study

E. coli Fg Aα1-560

pQE30

1-560 of mature Aα

This study

E. coli Fg Bβ

pQE30

Full length mature
(8)
Bβ
E. coli Fg γ

pQE30

Full length mature γ

(9)

L. lactis-vector

pKS80

Empty vector

(21)

L. lactis-Bbp

pKS80

Full length Bbp

This study

pCU1

Empty vector

(21)

S. aureus Newman
bald-vector
Full length Bbp (with
S. aureus Newman
pCU1

promoter and

This study

bald-Bbp
terminator)
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Lactococcus lactis-Bbp1615- The entire bbp coding region from strain S. aureus B504
(kindly donated by Ed Feil) was ligated into the pKS80 plasmid for constitutive expression.
The plasmid was transformed into Lactococcus lactis MG1363. This complemented strain
expresses Bbp on the surface of L. lactis under a constitutive promoter and was kindly
provided by Timothy Foster.

S. aureus Newman bald-Bbp – The strain S. aureus DU6023 clfA5 isdA clfB::Emr
ΔsdrCDE::Tcr (21) will be referred to as Newman bald and was used for expression of fulllength Bbp on the surface of the bacteria under the control of its native promoter as
previously described for other MSCRAMMs (21). Briefly, the DNA was amplified from S.
aureus MRSA252 (kindly provided by NARSA) using the primers listed in Table 3-2, and
subcloned into TOPO-Zero Blunt (Invitrogen) for transformation into E. coli TOP 10 cells.
The plasmid was digested with BamHI and XbaI; the insert was ligated to the shuttle vector
pCU1, and the plasmid was transformed into XL-10 Gold cells (Stratagene). Sequencing
was used to verify the integrity of the plasmid pCU1-Bbp. The plasmid was purified and
transformed into electrocompetent S. aureus 8325-4 and plated on BHIB with
chloramphenicol. Subsequently, pCU1-Bbp was electroporated into electrocompetent
Newman bald cells.

Bacterial adherence assays: Binding of L. lactis-Bbp or Newman bald-Bbp to the Fg Aα
truncation mutants was tested in crystal violet adherence assays. Microtiter wells were
coated with Aα1-575 and Aα1-560 in bicarbonate buffer overnight. The next day, the wells
were washed with phosphate-buffered saline (PBS), blocked with PBS-1%BSA, and
washed with PBS supplemented with 0.5 mM magnesium chloride and 0.1 mM calcium
chloride (PBS-Ca2+-Mg2+). L. lactis-Bbp and L. lactis-vector were grown overnight, washed
in PBS-Ca2+-Mg2+, and resuspended in PBS-Ca2+-Mg2+ at an OD600 of 1.0. Newman bald54

Bbp and Newman-bald vector were grown overnight, diluted 1:50, and grown to an OD600 of
0.6. The cells were washed and resuspended to an OD600 of 2.0 in PBS-Ca2+-Mg2+. The
blocked and washed wells were incubated with 0.1 ml of bacterial suspension for 1.5 hours
at 30°C for L. lactis or 37°C for Newman bald strains. The wells were washed with PBSCa2+-Mg2+, then fixed with paraformaldehyde (4%) for 30 minutes. After washing with PBSCa2+-Mg2+, the wells were incubated with crystal violet (0.5%) for 3 minutes. The wells were
washed and the crystal violet was dissolved in acetic acid (5%). The absorbance of the
wells was measured at 590 nm.

Synthetic peptides- Fg Aα peptides (Table 3-4) corresponding to the human sequences
551-575, 561-565, 556-570, 551-565, and a scrambled 51-575 were synthesized by
Biomatik.

Isothermal titration calorimetry (59)- The interaction between BbpN2N3 protein and soluble
Fg Aα 15mer or 25mer peptides (Table 3-4) was analyzed using a VP-ITC microcalorimeter
(MicroCal) at 30°C. The cell contained 15 µM BbpN2N3 and the syringe contained 225 µM
peptide in TBS. All samples were degassed for 5 min. The titration was performed with a
stirring speed of 300 rpm. The initial injection was 5 µl followed by 29 injections of 10 µl
with an injection speed of 0.5 µl/second. Data were fitted to a single binding site model and
analyzed using Origin version 5 (MicroCal) software.

Inhibition assay- BbpN2N3 (150 nM) was incubated with increasing concentrations of Fg Aα
peptides (0.1 to 30 µM) for 30 minutes before incubation in Fg coated wells. The wells
were incubated with rabbit-anti-BbpN2N3 and goat-anti-rabbit-HRP. The wells were
developed with SigmaFast OPD (Sigma), and the absorbance was measured at 450 nm
with a Thermo Max plate reader (Molecular Devices).
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Table 3-4. Peptides synthesized for this study
Peptide name

Peptide sequence

Fg Aα 551-575

FPSRGKSSSYSKQFTSSTSYNRGDS

Fg Aα Scrambled

GSSQTSKTSDFPRRYFSSKSYGNSS

Fg Aα 551-565

FPSRGKSSSYSKQFT

Fg Aα 556-570

KSSSYSKQFTSSTSY

Fg Aα 561-575

SKQFTSSTSYNRGDS

56

Fibrin inhibition assay- Using the previously described methods (22), thrombin-catalyzed
fibrin formation was studied.

Briefly, Fg coated wells were incubated with increasing

concentrations of BbpN2N3, SdrGN2N3, or BSA for 30 minutes prior to the addition of 1.0 NIH
unit of thrombin per milliliter. The turbidity of the wells was measured at 405 nm.
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RESULTS

Bbp is expressed in clinical isolates.
The presence of bbp has been correlated with both carriage and invasive S. aureus
isolates. In order to study the expression of Bbp from a clinical isolate, I obtained MRSA
252, which is a blood S. aureus isolate.

The cell-wall proteins were harvested from

exponentially growing cultures using lysostaphin digestion. Western blotting the extract
with anti-N1 monoclonal antibody revealed the presence of an approximately 175 kDa
protein, corresponding to full-length Bbp (Figure 3-2). The Western blot also shows another
band of approximately 50 kDa which is the detection of Protein A in the cell-wall extract.
Next, I probed the cell-wall extraction with an anti-BbpN2N3 affinity-purified polyclonal.
Western blotting with the N2N3 polyclonal antibody identified two bands of approximately
100 kDa and 175 kDa in all of the samples (Figure 3-2). In other Sdr proteins, cleavage of
the N1 domain by a metalloprotease has been documented (87). Therefore, the higher
band is the full-length Bbp, and the lower band is likely to be a form of the protein that is
missing the N1 domain. Also, Western blots with the N2N3 polyclonal showed a faint band
of lower molecular weight (approximately, 80 kDa) in early time points only (OD600 of 0.55
and 0.6). These results indicate that Bbp can be detected in vitro in a blood isolate.

BbpN2N3 binds to human fibrinogen.
To test the binding of Bbp to putative ligands, a construct that contains the putative
binding sites, the N2N3 domains, was designed (Figure 3-3). This construct was expressed
as a His-fusion protein and purifed with affinity and ion-exchange chromatography (Figure
3-4).
An initial screen was performed to examine the binding of recombinant His-tagged
BbpN2N3 (Figure 3-5a) in a solid-phase assay. Soluble BbpN2N3 (0.01 to 10.0 µM) was used
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Figure 3-2. In vitro expression of Bbp. S. aureus MRSA 252 cells were harvested
at OD600 = 0.55, 0.60, 0.70, 0.80, and 0.90 and the cell-wall proteins were extracted
with lysostaphin digestion. The extract was separated by SDS-PAGE, transferred to
nitrocellulose and blotted with anti-N1 domain monoclonal antibody (A) or antiBbpN2N3 affinity purified polyclonal antibody (B).
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Figure 3-3. BbpN2N3 construct. (A) Domain organization of full length Bbp (top) and BbpN2N3
(bottom) showing the (S) signal sequence, (N1, N2, N3) amino terminal subdomains of A
region, (B1, B2, B3) B-repeats, (SD) Serine-Aspartate repeat region, (W) wall domain, (M)
membrane domain, (C) carboxy-terminus. In BbpN2N3, (H) Hexahistidine tag. (B) Structural
model of the N2N3 subdomains of Bbp based on the structure of other MSCRAMMs. Betasheets are depicted in yellow. The N2 domain is at the bottom of the image, and the N3
domain is at the top.
A

B
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Figure 3-4. Purified BbpN2N3. (A) Coomassie stained recombinant BbpN2N3 (1
µg/lane). (B) Anti-His monoclonal immunoblot of purified BbpN2N3.
A

B
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to probe microtiter wells coated with extracellular matrix and plasma proteins, followed by
detection with polyclonal anti-BbpN2N3 and HRP conjugated anti-rabbit polyclonal. In this
assay, BbpN2N3 recognized Fg in a concentration-dependent, saturable manner but failed to
bind to Elastin, Collagen type I – IV, Laminin, Fibronectin, and BSA. To determine if soluble
Fg could bind to immobilized BbpN2N3 I performed the reverse assay. Wells coated with
increasing amounts of BbpN2N3 (0.25-2.5 µg) supported Fg binding (Figure 3-5b). These
results provide evidence for dose-dependent saturable binding between BbpN2N3 and Fg.
Next, I studied the specificity and affinity of the BbpN2N3-Fg interaction. First, the
species tropism of Bbp was examined using solid-phase assays. Wells coated with Fg
purified from human, cat, dog, cow, sheep, mouse, and pig were probed with BbpN2N3. Our
results indicate that BbpN2N3 only binds to Fg isolated from human plasma (Figure 3-6).
This is in contrast to the Fg-binding activity of ClfAN2N3, which exhibits a wider host tropism.
These results suggest that Bbp does not recognize a motif present in Fg from different
species but one that is specific to human Fg.
The dissociation constant of BbpN2N3 for Fg was examined using SPR. Binding of
BbpN2N3 (40 nM-2.56 µM) to Fg immobilized on a sensor chip was analyzed using a BIAcore
3000 (Figure 3-7a).

The equilibrium analysis revealed a KD of 540 +/- 7 nM of BbpN2N3 to

Fg (Figure 3-7b). Together, these data suggest that human Fg is a second ligand for
BbpN2N3.

BbpN2N3 recognizes the Aα chain of fibrinogen.
In order to determine whether Bbp targets one or multiple Fg chains, I used Far
Western analysis.

Fg was reduced in sample buffer containing β-mercaptoethanol to

dissociate the disulfide bonds that hold the two sets of three polypeptide chains together
and separated on SDS-PAGE (Figure 3-8a) followed by transferring to nitrocellulose
membrane for Far Western probing. In this assay, BbpN2N3 bound to the Aα chain of Fg,
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Figure 3-5. BbpN2N3 binding to Fg. (A) Ligand screen . Putative ligands were coated
on microtiter wells and probed with increasing concentrations (0.1-10 µM) of
BbpN2N3 followed by rabbit-anti-BbpN2N3 and goat-anti-rabbit-HRP. (B) Increasing
amounts of BbpN2N3 (0.25 to 2.5 µg) were coated on microtiter wells and probed
with 1 µM Fg followed by goat-anti-human Fg and donkey-anti-goat-HRP.
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Figure 3-6. Fg species screen. Microtiter wells were coated with 1 µg of
human, canine, feline, bovine, ovine, murine, or porcine Fg, or BSA in
bicarbonate buffer overnight. The wells were probed with 500 nM BbpN2N3
or ClfAN2N3, followed by protein specific rabbit polyclonal antibodies and
goat-anti-rabbit-HRP.
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Figure 3-7. BbpN2N3 Surface Plasmon Resonance. Two-fold linear dilutions
(2.56 to 0.04 µM ) of BbpN2N3 were injected over the Fg immobilized on a Biacore
sensor chip. (A) Response curves for each injection of BbpN2N3 (Black) are
overlaid with the global fitting to a 1:1 binding model (Red). Kinetic parameters
were obtained from the fitting. (B) Equilibrium analysis: Responses at
equilibrium of the SPR curves were fit to a one-site binding isotherm to obtain
the affinity and binding maximum. Experiment performed by Xiaowen Liang.
A

B
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while the previously characterized MSCRAMMs SdrGN2N3 and ClfAN2N3 bound to the Bβ and
γ chains, respectively (Figure 3-8b).
In order to verify our Far Western results obtained with reduced Fg, I tested binding
of BbpN2N3 to the individual Fg chains.

Recombinant full-length Aα, Bβ, and γ were

expressed as His-tagged constructs and purified (Figure 3-9a).

Individual chains were

immobilized on microtiter plates and probed for BbpN2N3 (15.6-500 nM) binding using a
solid-phase assay (Figure 3-9b). The Bβ and γ chains did not support binding, whereas
BbpN2N3 bound saturably in a concentration-dependent manner to plasma Fg and Aα.
Together, these results indicate that BbpN2N3 binds to a site localized to the human Fg Aα
chain.

The binding site of Bbp lies within residues 561-575 of the Fg Aα chain.
To map the Bbp N2N3 binding site, I used a systematic approach and constructed Cterminal truncates of the Aα chain (Figure 3-10a). The recombinant Fg Aα1-575 and Fg
Aα1-560 were purified (Figure 3-10b lanes 3 and 4, respectively) and examined for binding
activity.

Far western blots revealed that Aα1-575 retained the BbpN2N3 binding site;

however no binding was detected to Aα1-560 (Figure 3-10b), suggesting that no residues
N-terminal to 561 are necessary for binding. To further confirm our results, a solid phase
assay comparing the binding of BbpN2N3 to Aα1-560 and Aα1-575 revealed that only Aα1575 could support saturable, concentration-dependent binding (Figure 3-11a).

These

results indicate that the residues that mediate binding of BbpN2N3 to Fg lie in the Aα chain
between 561 and 575.
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Figure 3-8. Reduced Fg Far Western. Fg was reduced and separated on SDSPAGE followed by Coomassie staining (A) to reveal the three chains Aα (top band),
Bβ (middle band) and γ (bottom band) or electrotransferred for Far Western blotting
(B). Membranes were probed with BbpN2N3 (left), SdrGN2N3 (middle), and ClfAN2N3
(right). Followed by incubation with protein-specific rabbit polyclonals and goat-antirabbit-AP.

A

B
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Figure 3-9. Purified individual Fg chains. (A) Coomassie stained gel showing the
individually expressed and purified His-tagged Fg chain constructs compared with
reduced human Fg (left). (B) Fg , and recombinant individual Aα, Bβ, and γ chains
were coated on microtiter wells overnight in bicarbonate buffer. They were probed
with BbpN2N3 followed by anti-BbpN2N3 and goat-anti-rabbit-HRP.
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Figure 3-10. Aα truncation mutants.
Cartoon schematic of the full-length and
truncated Aα chain constructs. (B) Coomassie stained gel of Fg, recombinant Aα, Aα
1-575 and Aα 1-560, Bβ, and γ (top) and BbpN2N3 Far Western (bottom).
A

B
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Full-length Bbp binds to Fg Aα chain residues 561-575.
The apathogenic bacterium Lactococcus lactis has been successfully used as a
heterologous host for full-length MSCRAMM cell surface display (21).

Therefore, I

employed this method to determine whether Bbp expressed on the surface of a cell could
recognize the mapped residues. Using a bacterial adherence assay, I determined that L.
lactis-Bbp bound to plates coated with Aα1-575; whereas the empty-vector construct L.
lactis-pKS80 did not bind to Aα1-560 or Aα1-560 coated wells (Figure 3-11b). This result
indicates that full-length Bbp exhibits binding to the mapped residues.
The S. aureus Newman bald strain lacks surface expression of the MSCRAMMs
ClfA, ClfB, IsdA, IsdB, SdrC, SdrD, and SdrE (21). Therefore, this strain was used to
introduce full-length bbp under the control of its native promoter. The strains Newman baldpCU1 and Newman bald-Bbp were assessed for binding to Aα1-575 and Aα1-560 in an
adherence assay.

Newman bald-Bbp only adhered to wells coated with Aα1-575 in

contrast to the empty vector control, which did not recognize either Aα construct (Figure 311c). The data gathered with L.lactis-Bbp and Newman-bald-Bbp mimic the binding profile
exhibited by recombinant Bbp

N2N3.

These data indicate that Bbp on the surface of

staphylococcal bacteria can mediate binding to human Fg.

Characterization of the interaction between Bbp and peptides from Fg Aα.
In order to determine the affinity of the interaction between BbpN2N3 and Fg Aα
peptides, ITC was performed. Peptides (225 µM) in TBS were titrated into a cell containing
15 µM Bbp

N2N3

that had been dialyzed into TBS (Figure 3-12). The one binding site fit

model was used to analyze the data, which is summarized in Table 3-5. ITC analysis
showed that the peptides Aα551-575 and Aα561-575 bind to Bbp

N2N3

with a KD below 1

µM, indicating high-affinity binding. Furthermore, no binding was detected from the peptide
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Figure 3-11. Full-length and BbpN2N3 binding to Aα truncation mutants. (A) Aα 1-575 and
Aα 1-560 coated wells were probed with increasing concentrations (15-500 nM) of BbpN2N3,
followed by anti-BbpN2N3 antibody and anti-rabbit-HRP; (B) stationary-phase L. lactis-pKS80
and L. lactis-pKS80-Bbp, and (C) exponential-phase S. aureus Newman bald-pCU1 and S.
aureus Newman bald-pCU1-Bbp.
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Figure 3-12. Isothermal titration calorimetry of Fg Aα peptides and BbpN2N3. Binding of 225 µM peptides to 15 µM protein
was measured with a VP-ITC. The samples were degassed for 5 minutes and and 10 µl of the peptides were titrated at 0.5
µl/sec into the cell containing BbpN2N3. All experiments were conducted in TBS at 30°C with a stirring speed of 300 rpm.

Table 3-5. Isothermal Titration Calorimetry data

N

K

ΔH

ΔS

(kcal/mol)

(kcal/mol)

Kd (calc)

551-575

2.074

1.256E6

-1.269E4

-13.95

0.796 µM

Scrm

2.633

1.965E5

-8.296E3

-3.149

5.089 µM

551-565

N.D.

N.D.

N.D.

N.D.

N.D.

556-570

1.894

5.477E5

-1.039E4

-8.030

1.825 µM

561-575

1.902

3.227E6

-1.222E4

-10.51

0.309 µM
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Figure 3-13. Peptide inhibition. (A) BbpN2N3 (150 nM) was preincubated with
increasing concentrations (0.1 – 30 µM) of peptides prior to incubation in Fg-coated
wells. (B) Chart showing the peptide sequences and relative inhibition scores.
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Figure 3-14. Alignment of sequences from several species corresponding
to human Aα 561-575.
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Aα551-565, suggesting that these residues are not important for binding, and further
strengthening our data with the truncated Fg Aα chain mutants. The peptide Aα 556-571
exhibited binding with a KD of 1.8 µM. Therefore residues contained in this peptide can
mediate binding to BbpN2N3 albeit with less affinity.

Truncation analysis experiments

together with ITC indicate that BbpN2N3 binds specifically to Aα residues 561-575.
To further characterize the binding specificity of BbpN2N3 to Fg, I performed inhibition
experiments with the synthetic Fg Aα peptides. BbpN2N3 was preincubated with increasing
concentrations of peptides (0.1-30 µM) before addition to Fg coated wells in a solid-phase
assay (3-13a).

The Aα551-575, Aα561-575, and Aα556-570 peptides fully abolished

binding of BbpN2N3 to Fg. The scrambled peptide showed partial inhibition of binding, which
did not reach 100% inhibition. Additionally, the Aα551-565 peptide could not inhibit the
interaction. The results obtained from the inhibition assays are in direct accordance with
the data gathered in ITC experiments, meaning that the inhibitory activity imparted by the
peptides is directly related to their ability to bind to BbpN2N3 (Figure 3-13b).
A Clustal alignment of the Fg Aα 561-575 of Fg from many species was performed
(Figure 3-14).

The results indicate that the sequence of human, canine, and feline

fibrinogen are related. All three contain the second Aα RGD site; whereas only part of the
residues are present in porcine or bovine Fg. Furthermore, I observed that the rat and
murine sequences are distant from the human. These species do not contain the RGD site,
nor a stretch of polar, uncharged residues. The alignment data indicate that the feline and
canine Fg are the closest to human. The canine and human sequences only differ by two
residues, yet canine Fg does not support binding of Bbp.

76

Bbp inhibits fibrin formation
In order to examine the consequences of Bbp binding to Fg, I studied its effect on
fibrin formation. Fg-coated wells were pretreated with increasing concentrations of BbpN2N3,
SdrGN2N3, a Fg-binding MSCRAMM of S. epidermidis, as a positive control, or BSA as a
negative control prior to addition of thrombin. BbpN2N3 inhibited the formation of fibrin in a
concentration-dependent manner, and similarly to SdrGN2N3 (Figure 3-15a).

Human

thrombin is capable of cleaving the Fg of other species. Therefore, I examined whether the
effect on fibrin formation exerted by Bbp was species specific. The data show that Bbp N2N3
cannot inhibit thrombin-catalyzed fibrin formation from ovine Fg (Figure 3-15b). Our results
indicate that pre-treatment of Fg with Bbp inhibits thrombin-catalyzed fibrin formation.
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Figure 3-15. Inhibition of fibrin formation. Increasing concentrations (0.03 – 10 µM) (A)
or 1 µM (B) of BSA, SdrGN2N3, or BbpN2N3 were preincubated in human Fg-coated (A and
B) or ovine Fg-coated (B) wells prior to the addition of α-thrombin.
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Discussion
S. aureus uses a multitude of virulence factors to cause a wide range of diseases.
The MSCRAMMs can mediate binding of S. aureus to host proteins, thereby facilitating
colonization. MSCRAMMs, including the Sdr family of proteins, are capable of recognizing
many ligands. Here, the identification of human Fg Aα as a second ligand for Bbp is
reported.
The data indicate that a strong interaction occurs between the two proteins.

I

observed that BbpN2N3 was capable of binding to immobilized as well as reduced Fg, and
recombinant, denatured Fg Aα chain, which is typical of Fg-binding MSCRAMMs (Figure 35a, 8b, 10b, 11). These data indicate that the MSCRAMM binds to a linear sequence in the
ligand. Furthermore, Biacore experiments with immobilized Fg resulted in a KD of 540 nM,
(Figure 3-7) and the KD generated from ITC with peptide Aα561-575 was 309 nM (Figure 312). The affinities gathered with the two methods have similar values. It is possible that the
affinity was lower in Biacore experiments due to the immobilization of Fg, as this may have
hidden or obscured the available binding site for BbpN2N3. Additionally, ITC was performed
with both the peptide and the protein in solution, with stirring, and in a 5°C warmer
atmosphere. Therefore, the experimental conditions in ITC may have been more conducive
to the binding events between BbpN2N3 and the Aα peptides.
Also speaking to the specificity of the interaction is that Bbp only targets human Fg
(Figure 3-6).

Alignment of the sequences corresponding to the human Fg Aα561-575

revealed small differences among the residues present in human, feline, and canine Fg
(Figure 3-14). Specifically, the canine sequence contains an extra hydrophobic residue at
position 565. This offsets the stretch of polar, uncharged residues found between 565 and
571 by one position. Also, Ser569 in humans is a Thr in the canine sequence. Although
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these are the only two differences between the human and canine sequences, they are
enough to abrogate BbpN2N3 binding to canine Fg.
The results obtained with recombinant BbpN2N3 were confirmed using constructs that
express the full-length protein on the surface of two heterologous hosts. L. lactis and S.
aureus Newman bald provided a platform to study the binding contribution from a single
MSCRAMM in prior studies (21).

In this study, Bbp on the surface of both bacteria

mediated attachment to immobilized Aα1-575 but not to Aα1-560 (Figure 3-11b, c). These
data indicate that the full-length protein under the control of its native promoter can lead to
Fg adherence.
The binding site of BbpN2N3 was mapped to Aα561-575, which ends with the second
RGD site of the Aα chain. Reports have suggested a role for the second Aα RGD in binding
to the integrins α5β1 and αVβ3 (120) (119). Although further studies are required in order to
determine what downstream effects occur upon Bbp binding to Fg, one possible effect
could be the abrogation of the Fg Aα-integrin interaction.
The effects of the Bbp-Fg interaction on clotting were examined. We detected an
abrogation of fibrin formation when Fg was preincubated with Bbp. The residues Aα561575 to which we have mapped Bbp binding lie in the αC domain of Fg. This domain may
mediate binding between fibrils to form fibrin. Also the residues are adjacent to a proposed
transglutaminase target (116).

Further experiments will determine the effects of Bbp

binding on lateral association of fibrin monomers into crosslinked fibrin.
BSP was previously described as a ligand of Bbp, and this interaction may play a
specific role in facilitating S. aureus osteomyelitis. Osteomyelitis is an infection of the bone,
which may be accompanied or caused by hematogeneous spread. It is possible that Bbp
may function in two capacities: as an important factor in osteomyelitis and as a contributing
factor in S. aureus hematologic diseases, such as sepsis. Future studies regarding the
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expression profile of Bbp in certain disease settings or disease-specific models may aid in
elucidating the contribution of Bbp to S. aureus pathogenesis.
Fg was identified as a novel ligand for the MSCRAMM Bbp. The binding site was
mapped to the residues 561-575, which represents a novel MSCRAMM target in Fg. Also,
the interaction of Bbp with Fg inhibits the formation of fibrin. Future studies will further
define the consequences of Bbp binding to Fg.
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CHAPTER IV
Binding mechanism of Bbp to fibrinogen
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CHAPTER IV
Binding mechanism of Bbp to fibrinogen

Introduction
The binding that occurs between MSCRAMMs and their ligands has been shown to
be a dynamic event that can result in conformational changes. This is the case for the
fibronectin-binding MSCRAMMs of Borrelia burgdorferi, Streptococcus pyogenes and S.
aureus (105) (113). The Fnbps from these bacteria form a tandem-beta zipper upon ligandbinding.

Also, the collagen adhesins, Cna and Ace from S. aureus and Enterococcus

faecalis, respectively, bind to their ligand through the collagen hug model (142) (80). The
S. epidermidis fibrinogen-binding protein, SdrG binds via the dock, lock, and latch (DLL)
model (102). Furthermore, ClfA binds to Fg via a variant of the DLL mechanism (43).
Evidence gathered from alanine scanning, truncation analysis, peptide studies, and
crystallization has permitted the elucidation of the binding mechanisms of MSCRAMMs.
The A region of SdrG, ClfA, Cna, and Ace is subdivided into immunoglobin-like N
subdomains and contains the ligand-binding domains. The collagen-binding MSCRAMMs
have a ligand-binding pocket between the N1 and N2 subdomains; whereas, the ligandbinding site of fibrinogen-binding MSCRAMMs is located between the N2 and N3
subdomains.
The dock, lock, and latch mechanism of SdrG binding to the Fg Bβ was elucidated
using biochemical and structural assays.

In the unbound, apo-SdrGN2N3 structure the

MSCRAMM is in an open conformation with an unoccupied ligand-binding trench. A cocrystal of the complex formed by SdrGN2N3 with the Bβ6-20 peptide showed that the
MSCRAMM is in a closed conformation after ligand binding (102). In the latter structure,
the N3 extension, or latch, is inserted into the N2 domain and forms a complemented β-
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sheet (102). Additionally, the co-crystal provides information about the interacting residues
in both the MSCRAMM and the peptide.
To provide more evidence for the DLL, experiments were performed with truncation
mutants. The SdrGN2N3 was truncated to determine that the latching event was necessary
for ligand binding.

Furthermore, the open and closed conformations were covalently

engineered by the insertion of cysteine residues into SdrG N2N3 (10).

Because the Sdr

proteins are similar in domain organization and folding, the dock, lock, and latch
mechanism of binding has been proposed for this family of MSCRAMMs.
The collagen hug model of Cna and Ace (from Enterococcus faecalis) is similar to
DLL. One striking difference is that the N1 and N2 domains have a longer linker region that
accommodates the collagen triple helix. Upon ligand binding, Cna and Ace wrap around or
“hug” the collagen peptide. The N1, linker, and N2 ultimately form a tunnel where the
collage peptide is bound (142).

Similar studies to those performed for SdrGN2N3 with

constructs that are permanently open or closed, or that have mutations in the C-terminal
extension or “latch” were used in experiments to support the collagen hug binding
mechanism (Figure 4-3) (80).
Bbp is an MSCRAMM implicated in S. aureus osteomyelitis.

It has been

demonstrated that Bbp binds to bone-sialoprotein, a component of bone and dentin.
Because targeting multiple ligands is a common trait among previously characterized
MSCRAMMs, I determined whether Bbp followed this trend. In previous studies I identified
the binding site of Bbp on human Fg Aα. Importantly, Fg binding from full-length Bbp
expressed on the surface of heterologous hosts was detected (Figure 3-11). The binding
residues on the Fg Aα chain include an RGD site, which suggests that the binding of Bbp
may inhibit normal fibrinogen signaling (Figure 3-14). Furthermore, I determined that Bbp
inhibits fibrin formation (Figure 3-15). MSCRAMMs use dynamic mechanisms to bind to
their ligands. Sequence similarity and structural modeling suggest that of BbpN2N3 may bind
84

to fibrinogen in the same fashion as other MSCRAMMs. I sought to decipher the binding
mechanism between Bbp and fibrinogen.
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Materials and Methods
Commercial reagents: The reagents used for this chapter are described in Chapter II.

Design of BbpN2N3 mutants by MSCRAMM comparison - Clustal sequence alignment was
performed on the amino acid sequences corresponding to the N2N3 domains of Bbp, SdrG
and ClfA, and the structure of BbpN2N3 was modeled based on solved MSCRAMM
structures using Ribbons (Chapter III, Figure 3-3). The Bbp lock truncation is at Ile583 and
the Bbp latch residues begin at Ser589. A disulfide bond mutant was constructed with the
substitutions E376C and P598C.

BbpN2N3 mutants- S. aureus MRSA 252 genomic DNA was used as template to amplify the
DNA corresponding to Bbp 270-582 (ΔLock and latch) and 270-588 (ΔLatch), and 270-599
E376C / P598C sequences using the primers listed in Table 4-1.

The products were

subcloned into TOPO Zero Blunt vector and transformed into TOP3 cells. After sequence
verification, the plasmids were digested and inserts were ligated into pQE30 for
transformation into XL1 Blue cells. E. coli-BbpN2N3ΔLock, E. coli-BbpN2N3ΔLatch, and E. coliBbpN2N3E376C/P598C (BbpCys-Cys) were cultured to exponential phase, induced with 200
µM IPTG, and grown for an additional 3 hours.

The cells were pelleted, lysed, and

purification of mutants was accomplished using Ni2+ affinity chromatography as previously
described (22) on a HiTrap Chelating column

Fractions were analyzed by SDS-PAGE,

pooled, and dialyzed for anion exchange-purification using a Q HP Sepharose. To assess
purity, the proteins were run on 10% SDS-PAGE and stained with Coomassie blue.

The

BbpCys-Cys construct was run under both nonreducing and reducing conditions to verify
the formation of a disulfide bond.

The nonreduced sample appeared smaller than the

reduced sample.
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Table 4-1. Oligonucleotides used in this study

Primer name

Oligonucleotide sequence

pQE30N2N3For

CGGGATCCGTTGCTTCAAACAATGTTAAT

pQE30LockRev

CGAAGCTTTTAAGTATTAGTGTAACCTGCATA

pQE30LatchRev

CGAAGCTTTTAGTCAGTAGTTGATAAAATAGT

Bbp376CRev

GACATTCTCACATCTATCAAC

Bbp376CFor

GTTGATAGATGTGAGAATGTC

Bbp598CRev

CCCAAGCTTTTATTCAGGTTTACAAGATACCGCAC
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Solid-phase binding assays- Fg was coated on microtiter wells overnight in bicarbonate
buffer at 10 µg/ml. The wells were blocked with Superblock and probed with increasing
concentrations (0.1 – 10 µM) of BbpN2N3, BbpN2N3ΔLock, and BbpN2N3ΔLatch and detected
with anti-BbpN2N3 and anti-rabbit-HRP. The wells were developed and the absorbance was
measured at 450 nm. To assess the binding of the BbpCys-Cys, Fg-coated wells were
incubated with the BbpN2N3 or BbpCys-Cys in the presence or absence of 5 mM dithiothreitol
(DTT).

BbpCys-Cys Far Western- Laemmli sample buffer containing 10 mM DTT was added to Fg
for SDS-PAGE separation followed by transferring to nitrocellulose. The membranes were
blocked with 1% BSA and probed with BbpCys-Cys (15 µg/ml) in the presence or absence
of 5 mM DTT in TBST, followed by detection with anti-BbpN2N3 and anti-rabbit-AP.
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RESULTS

BbpN2N3 mutants were designed by MSCRAMM comparison.
To reveal the locking and latching sequences and closed disulfide bond locations in
Bbp, two approaches were taken. First, the amino acid sequences corresponding to the
N2N3 domains of Bbp, SdrG and ClfA were aligned using Clustal (Figure 4-1). Second, the
structure of BbpN2N3 was modeled based on solved MSCRAMM structures using Ribbons
(Figure 3-3). The analyses revealed that the lock and latch truncations are at Ile583 and
Ser589, respectively. Furthermore, structural analysis predicted that the residues Glu376 and
Pro598 are positioned in a way that if substituted to Cys, they can form a disulfide bond.
Therefore, BbpN2N3 containing the substitutions E376C and P598C was constructed.

The lock and latch are necessary for BbpN2N3 binding.
In order to assess whether the binding of BbpN2N3 to Fg is dependent upon the
locking and latching residues, a solid-phase ELISA-type assay was conducted. Increasing
concentrations of soluble BbpN2N3,, BbpN2N3ΔLock, and BbpN2N3ΔLatch (0.01 to 10.0 µM)
were used to probe microtiter wells coated with Fg, followed by detection with polyclonal
anti-BbpN2N3 and HRP conjugated anti-rabbit polyclonal. In this assay, BbpN2N3 recognized
Fg in a concentration-dependent, saturable manner but BbpN2N3ΔLock and BbpN2N3ΔLatch
failed to bind to Fg (Figure 4-2b). This indicates that the binding of Bbp to Fg requires the
carboxy-terminal residues in the lock and latch sequences.

An open conformation is required for BbpN2N3 binding to Fg.
I determined whether an engineered disulfide bond could force the protein into a closed
conformation. SDS-PAGE in the absence or presence of reducing agent indicated that the
reduced protein was larger in size. This suggests that the reduction of disulfide
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Figure 4-1. Alignment of the N2N3 domains of SdrG, ClfA, and Bbp. Red - conserved motif;
green – lock; yellow – latch; blue – cysteine mutations.
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Figure 4-2. Delta lock and latch BbpN2N3 mutants. (A) Coomassie stained SDSPAGE of BbpN2N3,, BbpN2N3ΔLock, and BbpN2N3ΔLatch. (B) Fg-coated wells were
incubated with increasing concentrations of BbpN2N3,, BbpN2N3ΔLock, and
BbpN2N3ΔLatch (0.01 to 10.0 µM) followed by anti-BbpN2N3 and anti-rabbit-HRP.
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bonds in the sample slows the migration, presumably due to the larger, open conformation
of the protein (Figure 4-3a).
The binding to Fg by a double cysteine mutant that formed a disulfide bond between
the N2 and N3 domains rendering the molecule in a closed form was examined. Fg-coated
wells were probed with increasing concentrations (15 – 1000 nM) of BbpN2N3 or BbpCysCys. Results indicate that the closed form of BbpN2N3 does not bind to Fg (Figure 4-3b).
In order to verify that the abrogation of binding was caused by the closing of the
binding site, experiments were performed to rescue the binding of BbpCys-Cys. Far
Western blotting was used to compare binding of reduced and nonreduced BbpCys-Cys
(Figure 4-4a). A Fg blot probed with BbpCys-Cys in the absence of DTT did not result in
signal detection. However, probing with BbpCys-Cys in the presence of DTT resulted in
binding. Furthermore, I performed a similar analysis using a solid-phase binding assay.
Fg-coated wells were incubated with BbpN2N3 and BbpCysCys in the presence of 5 mM DTT
(Figure 4-4b). The results indicate that re-opening the closed form of Bbp by disulfide
reduction restores the binding of BbpCys-Cys to similar levels as those of BbpN2N3.
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Figure 4-3.
BbpCys-Cys.
(A)
BbpCys-Cys was separated on SDS-PAGE in
nonreducing and reducing buffer. (B). Fg-coated wells were incubated with increasing
concentrations (15 – 1000 nM) of BbpN2N3 or BbpCys-Cys followed by anti-BbpN2N3
polyclonal antibody and anti-rabbit-HRP.
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Figure 4-4. Rescue of BbpCys-Cys binding. (A) Reduced Fg was separated on SDSPAGE and transferred to nitrocellulose membrane for Far Western analysis with
BbpCys-Cys (15 µg/ml) in the presence (left) or absence (right) of 5 mM DTT followed by
rabbit-anti BbpN2N3 polyclonal antibody and goat-anti-rabbit-AP. (B) Fg-coated wells
were incubated with increasing concentrations of BbpN2N3 or BbpCys-Cys in the presence
of 5 mM DTT followed by anti-BbpN2N3 and anti-rabbit-HRP.
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DISCUSSION

The dock, lock, and latch, or variant thereof, has been proposed as the binding
mechanism for MSCRAMMs. In this study, BbpN2N3 mutants were constructed to examine
the effects on binding imparted by the presence of the residues in the carboxy-terminus of
the N3 domain known as the lock and latch residues.
In the S. epidermidis MSCRAMM SdrG, ligand binding induces conformational
changes that include a redirection of the locking residues followed by β-strand
complementation that morphs the protein into a closed form with the ligand inside of the
binding trench. Therefore, appropriate BbpN2N3 constructs were designed by the aid of
computer modeling and sequence alignment. These constructs were used to evaluate the
regions required for Bbp to bind to Fg. Results indicate that BbpN2N3 requires both the lock
and latch for binding. Additionally, a disulfide-bonded closed mutant did not bind to Fg, but
the binding was restored by reduction of the disulfide bond, indicating that the protein must
be open for Fg binding. Therefore, the evidence strongly suggests that Bbp binds to Fg
using the dock, lock, and latch model.
Further studies are required in order to prove our hypothesis. To date, the structure
of the ligand binding domains of Bbp either in apo-form or in a complex with the ligand have
not been solved. Once the structures of the different forms of Bbp are solved, the residues
in the protein that bind to the target can be analyzed. Structural assessment of the two
forms of BbpN2N3 will support the evidence I have gathered biochemically.
Previous studies identified that Bbp inhibits fibrin binding. Although no data has
been gathered to examine this inhibition in more detail, the dynamic dock, lock, and latch
mechanism could be playing a role. The latching of the Fg molecule into the ligand-binding
trench could render the αC domain unavailable for lateral aggregation of fibrils and could
inhibit Factor XIIIa from covalently crosslinking the chains.
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The species tropism of Bbp poses some challenges in designing future experiments.
The previous study indicated that Bbp was highly specific for the human Fg sequence.
Therefore, it is possible that in order to progress to animal studies utilizing Bbp, partially
humanized Aα mice will be required.

Until such a model is available, conducting

biochemical, structural, and in vitro experiments will provide further understanding of the
interaction between Bbp and Fg. Moreover, the consequences of Bbp binding to fibrinogen
can be studied.
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Current staphylococcal therapy involves antibiotic use.

However, this is not a

preventive approach to halt the spread of staphylococcal infections. Preclinical and clinical
vaccine studies have targeted bacterial surface and secreted factors. A combination, or
multivalent, vaccine that targets several factors could prove to be successful.

In the

present studies, I sought to analyze two potential virulence factors.
In the second chapter, the epidemiologically suggested link between the PantonValentine Leukocidin (PVL) and necrotizing pneumonia was analyzed.

Using a murine

model of pneumonia, the ability of a highly purified PVL toxin preparation to cause
pneumonia (71) was discovered. Furthermore, the ability of the toxin subunits to elicit a
protective response was examined (13).

LukS-PV-vaccinated animals exhibited less

morbidity and mortality when challenged with a lethal dose of the S. aureus strain USA300,
which is a predominant antibiotic resistant clone causing CA-MRSA infections.
While the results were able to attribute necrotizing pneumonia to the PVL toxin, the
mechanism for this event has not been fully elucidated. As previously discussed, PVL lyses
monocytes, macrophages, and polymorphonuclear cells, and this interaction can lead to
leukocyte release of inflammatory mediators.

Future experiments are needed to fully

decipher the mechanisms by which PVL causes the severe inflammatory response
observed in the lungs of mice instilled with purified protein. Specifically, whether the toxin
itself can cause necrotizing pneumonia in leukocyte-deficient mice has not been determined
because these mice experience high morbidity upon staphylococcal exposure. A different
approach to gather valuable information would be to use mutant PVL that cannot
oligomerize or cause cell lysis.

This method was successful for the closely-related α-

Hemolysin.
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In the third and fourth chapters, data from experiments conducted with the cellsurface adhesin, Bbp, are presented. Bbp binds to bone-sialoprotein, indicating a role in
osteomyelitis. The ability of MSCRAMMs to bind to multiple ligands has been documented
for several proteins, and this work identified a novel ligand for the MSCRAMM Bbp. Also,
experiments were performed to decipher the binding mechanism of Bbp to Fg.
Screening a panel of typical MSCRAMM ligands for Bbp binding resulted in the
identification of fibrinogen (Fg) as a target for Bbp (Figure 3-5).

The binding site was

mapped to the αC region, residues 561-575, and peptide studies confirmed the results
(Figures 3-11, 3-12, and 3-13). Furthermore, Bbp exhibits high specificity and affinity for
human Fg (Figures 3-6 and 3-7).
I am beginning to examine the consequences of Bbp binding to Fg. Already, I have
accumulated data showing that Bbp inhibits fibrin formation (Figure 3-15). However, the
mechanism underlying this phenomenon has not been studied. It is likely that binding of
Bbp to the αC domain causes steric hindrance that inhibits the lateral aggregation of
protofibrils to form fibrin. Furthermore, the transglutaminase Factor XIIIa covalently links
the α chain to itself and to γ chains. The binding site, and surrounding residues, on αC
contain amino acids that are believed to be involved in crosslinking of fibrin (116).
Therefore, this is a possible mechanism of inhibition. Studies conducted with αC mutants
may aid in deciphering the mechanism by which Bbp inhibits fibrin formation.
The binding site of Bbp on Fg contains an RGD motif. This specific RGD has been
shown to bind to integrins present on endothelial cells, platelets, and fibroblasts.

No

experiments have been performed to examine the effects of Bbp on Fg-integrin binding.
Presumably, binding of Bbp to αC would occupy the integrin-binding site, or, at the very
least, the residues immediately amino-terminal to the integrin binding RGD. Therefore, I
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expect that pretreatment of αC with Bbp would directly inhibit or sterically hinder the
integrin-Fg interaction.
The mechanism of Bbp binding to Fg was studied. The data gathered indicate that
this interaction occurs via the dock, lock, and latch (DLL) model. Currently, our laboratory
is working to obtain a co-crystal structure of Bbp with a Fg peptide. A solved structure
would provide the evidence necessary to identify the residues in Bbp that interact with the
amino acids in human Fg. These data could pave the way for the design of inhibitors to
abrogate the interaction. Because the Bbp binding site includes an RGD site, care must be
taken not to inhibit important interactions between Fg and integrins necessary for normal
biological functions. For example, our laboratory recently reported the identification of
peptides that inhibit the interaction between ClfA and Fg but have no effect on the
interaction between Fg and the platelet integrin (43).
Evidence suggests that MSCRAMMs can serve as protective targets for a
staphylococcal vaccine. Therefore, our laboratory has worked to identify the molecular
interactions between the surface adhesins and the human host. Interestingly, Bbp has
been previously termed as an allelic variant of SdrE.
comparison to Bbp.

I have begun to study SdrE in

The two variants have been subjected to sequence alignment for

comparison (Figure 5-1). Interestingly, this analysis revealed that the N2N3 domains have
the highest sequence variation (approximately 60% identity), but the N1, B repeats, and SD
regions have identities above 90%.

Furthermore, a crystal structure of the SdrE N2N3

domains has been solved (Unpublished data by Dr. Vannakambadi Ganesh). A model of
BbpN2N3 based on the SdrEN2N3 structure indicates that the structure of BbpN2N3 is more rigid
in nature (Figure 5-2).

Specifically, the β-strands that compose the β-sandwiches are

longer in BbpN2N3; whereas in SdrEN2N3, the β-sheets are shorter, requiring more inter-strand
linker regions.
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Figure 5-1. Alignment of full-length SdrE (top row) and Bbp (middle row) showing the consensus sequence (bottom row).
The boxed area corresponds to the N2N3 domain of both proteins. Alignment performed using MacVector software.

Figure 5-2. Structural comparison of SdrE and Bbp. The N2 domains are at the bottom
and the N3 domains are at the top of the images.
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The added flexibility of the SdrEN2N3 domains was predicted to correlate with activity.
Preliminary experiments examining the differences in binding abilities and specificity were
performed with the two variants. First, the ability of SdrEN2N3 to bind to Fg was examined
(Figure5-3a). The results indicate that SdrEN2N3 binds to Fg in a concentration-dependent,
saturable manner. Furthermore, a species screen revealed that SdrEN2N3 exhibits a wider
species tropism for Fg than BbpN2N3 (Figure 5-3b). Human, feline, canine, bovine, ovine,
rat, and porcine Fg all supported binding to SdrEN2N3, albeit at different levels. Next, I
determined if the increased flexibility and tropism of SdrE affected its activity towards
human Fg.

A fibrin inhibition assay revealed that SdrEN2N3 was capable of inhibiting

thrombin-catalyzed fibrin formation to similar levels as BbpN2N3 (Figure 5-3c). However, a
higher concentration of SdrEN2N3 is required to reach maximum inhibition.

These

preliminary data indicate differences in the structure and activities of the ligand binding
domains of SdrE and Bbp. Future experiments to biochemically define the differences
between the two proteins could be performed with the same reagents that were used to
study the interaction between Bbp and Fg.

Although the data with SdrE and Fg are

preliminary, I have identified the only known ligand of SdrE.
The MSCRAMMs IsdA, IsdB, SdrD, and SdrE were identified as protective targets in
an intravenous infection model (118). Vaccination with SdrE led to high antibody titers and
a reduction of bacteria in the kidneys. Considering the data generated with SdrE and Bbp,
it is possible that Bbp could also serve as a protective immunogen. However, Bbp was not
examined in that study. It is also important to note that animal studies with Bbp may not be
fully translational to human disease because it only targets human Fg. Therefore, future
experiments examining the in vivo role of Bbp may require the utilization of mice with
partially humanized Fg.
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Figure 5-3. Comparison of SdrEN2N3 and BbpN2N3 activities. Human (A) or other species
(B) Fg-coated wells were incubated with increasing concentrations (50-1000 nM) (A) or
500 nM SdrEN2N3 and BbpN2N3 followed by protein-specific antibodies and goat-anti
rabbit-HRP. (C) Human Fg coated wells were preincubated with 0.03-10 µM proteins
prior to α-thrombin addition.
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The studies encompassing this dissertation provide new functional data regarding
putative staphylococcal virulence factors.

Studying putative virulence factors in animal

models of disease can provide urgent information necessary for the understanding of
complicated disease states.

Furthermore, identification of novel ligands for bacterial

proteins can lead to the discovery of virulence mechanisms.
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